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ABSTRACT
Thyroid cancer is the most common endocrine malignancy and his global incidence has rapidly 
increased in last decades. Despite the major part of thyroid cancer is represented by well 
differentiated hystotypes, the acquisition of additional mutations, such as p53 and β-catenin ones, 
causes loss of differentiation and confer high malignancy. Current treatment for undifferentiated 
thyroid cancers is regarded as almost ineffective, with a median survival of 3- 4 months, 
somewhat better in localized and worse in metastatic disease. 
SP600125 is a multi-kinase inhibitor that has recently been shown to be a promising anticancer 
drug. In the last five years it has been proved able to induce endoreduplication and subsequent 
polyploidization, but there are contrasting results about its intracellular actions and there is no 
evidence on the specific mechanism of action. Moreover, in 2012, SP600125 has been found to 
be the most effective against p53 deficient cells among more than 300 screened compounds. 
However, opposite results have also been obtained depending on cell type, concentration and 
time of incubation. 
In the current study the effects of micromolar doses of SP600125 have been characterized in six 
thyroid cancer cell lines with different p53 status. The results show that at low concentrations 
SP600125 dramatically reduces the proliferation of p53 mutated cells, with lesser effects on p53 
null and no effects on the wild-type ones. In p53 mutated cells it has been proved able to induce 
p53 nuclear translocation and phosphorylation at serine 15; this modification resulted to be 
responsible of increased levels of p21.
Importantly other considerable novel effects have been revealed. Firstly, SP600125 caused 
alterations of microtubule dynamics in p53 mutated cells, with increase of acetylation levels and 
loss of Microtubule Organizing Center (MTOC)-periphery organization. These effects were 
accompanied by alterations in cellular morphology and in late endosome/lysosome trafficking. 
Endoreduplication and alteration of microtubule dynamics finally resulted in aberrant mitosis 
and cell death. The second mechanism involves alteration of cellular motility: different kinases 
involved in this process are affected by SP600125 treatment and β-catenin remains at the 
intercellular junctions in affected cells,consistent with a failure of cell detachment (a figure 
consistent with inhibition of cell migration/motility). Microtubule alterations concomitantly also 
account for motility alterations. Both tubulin and β-catenin variations are due to HDAC6 activity 
alterations. This enzyme regulates the levels of acetylation of these proteins and is profoundly 
inhibited following SP600125 in p53 deficient cells. Alteration of HDAC6 activity is 
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hypothesized to be the result of SP600125 direct inhibition of ROCK2, an upstream kinase 
regulator of HDAC6 activity.
In conclusion SP600125 is a promising drug particularly active on p53-mutated cancers at 
concentrations unable to affect normal cell viability. The effects of SP600125 action include 
arrest of tumor growth, and importantly induction of tumor cell death and metastatic diffusion 
inhibition.  
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INTRODUCTION
1.1 THYROID CANCER: EPIDEMIOLOGY AND CLASSIFICATION
Thyroid cancer is the most common endocrine malignancy and his global incidence has rapidly 
increased in last decades [1]; every year it is responsible of more deaths than all other endocrine 
cancers combined [2]. Although the death rate is relatively low, disease recourrence or 
persistence is high, particularly for more advanced ones. It is estimated that in US 62,980 men 
and women will be diagnosed with and 1,890 men and women will die of cancer of the thyroid in 
2014 [3-4]. There is a significant prevalence in female vs. male incidence with a 3:1 ratio; 
incidence rates reach a peak around 50 years of age for women and 60 years for men.
Fig 1. Thyroid cancer incidence and mortality rates. SEER epidemiological data [3].
Fig 2. Thyroid cancer incidence and mortality rates in European Countries. IARC epidemiological data [5].
3
INTRODUCTION
Worldwide incidence rates are highly variable probably as a result of local environment, age, sex 
and ethnical influences [2].  Rates have been observed to be high in certain geographic areas 
such as Hawaii, particularly among Chinese and Filipinos, while rates in Poland are among the 
lowest recorded [2, 6]. 
In the last 50 years thyroid cancer incidence has more than doubled, with highest increase in 
papillary histotype, mainly due to new small sized tumors diagnoses; There was no significant 
change in the incidence of the less common histological categories: follicular, medullary, and 
anaplastic [7-8]. Despite increasing incidence, the mortality from thyroid cancer has remained 
stable through years.
There are different types and subtypes of thyroid cancers, classified by cellular origins, 
characteristics and prognoses [9]. Follicular thyroid cells derived tumors include papillary 
thyroid cancer (PTC), follicular thyroid cancer (FTC), poorly differentiated thyroid cancer 
(PDTC) and anaplastic thyroid cancer (ATC); parafollicular C cells derived cancers are 
medullary thyroid cancers (MTC). 
 o
ri
gi
n Tumor type Standard care and 
prognosis
Characteristics
Fo
lli
cu
la
r t
hy
ro
id
 c
el
ls
Papillary 
Thyroid 
Cancer
(PTC)
Thyroidectomy and, in 
selected cases, 
radioiodine ablation; 
novel drugs for resistant 
disease. 
Good overall prognosis.
Well differentiated, with papillary architecture and characteristic 
nuclear features that include enlargement, oval shape, elongation, 
overlapping and clearing, inclusions and grooves; propensity for 
lymphatic metastasis; PTC subtypes include conventional PTC 
(CPTC), follicular-variant PTC (FVPTC), tall-cell PTC (TCPTC) 
and a few rare variants.
Follicular 
Thyroid 
Cancer
(FTC)
Thyroidectomy and 
radioiodine ablation; 
novel drugs for resistant 
cases. 
Good overall prognosis.
Well differentiated, hypercellular, microfollicular patterns, lacking 
nuclear features of PTC; vascular or capsular invasion; propensity 
for metastasis via the blood stream; Hürthle cell thyroid cancer is 
a unique subtype of FTC that accounts for 2–3% of thyroid 
cancers and is characterized by large, mitochondria-rich oncocytic 
cells and dense nuclei and nucleoli, as well as a high propensity 
for metastasis and a poor prognosis.
Poorly 
Differentiated 
Thyroid 
Cancer
(PDTC)
Surgery,  chemotherapy, 
radiotherapy, novel drugs.
Poor prognosis.
Poorly differentiated, often overlapping with PTC and FTC; 
intermediate aggressiveness between differentiated and 
undifferentiated thyroid cancers.
Anaplastic 
Thyroid 
Cancer
(ATC)
Surgery, chemotherapy, 
radiotherapy, novel drugs, 
palliative care.
Highly and rapidly lethal.
Undifferentiated; admixture of spindle, pleomorphic giant and 
epithelioid cells; extremely invasive and metastatic; highly lethal; 
may occur de novo or derive from PTC, FTC or PDTC.
C
 c
el
ls Medullary 
Thyroid 
Cancer (MTC)
Surgery, chemotherapy, 
radiotherapy, novel drugs. 
Moderate aggressiveness, high propensity for lymphatic 
metastasis; RET mutation; occurring in familial, MEN2 or 
sporadic forms.
Table 1. Main thyroid tumors and their characteristics. Adapted from [10]
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Fig 3. Histological subtypes statistics. Epidemiological data from [3, 5]. 
1.2 THYROID CANCER: PATHOGENESIS AND GENETIC 
ALTERATIONS
Thyroid cells proliferation depends on the combined activation of cAMP/PKA, MAPK and PI3K 
pathways, as a result of TSH or Growth Factors stimulation; it is well known that alterations in 
genes involved in these signalling pathways play a prominent role in the development of thyroid 
cancer.
Fig 4. Pathways involved in thyroid tumorigenesis. Thyroid cell proliferation depends on the combined activation 
of cAMP/PKA, MAPK, and PI3K pathways, induced by TSH and other growth factors. Mutations of effectors along 
these signaling pathways play prominent roles in the pathogenesis of thyroid neoplasia. Adapted from [11].
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Thyroid cancer pathogenesis is classically view as an accumulation of different genetic 
alterations that drive progression through a dedifferentiation process [11-12].
Fig 5. Step model of thyroid carcinogenesis. The well-differentiated thyroid follicular cell may give rise to both 
benign and malignant tumors. After gaining mutations in different oncogenes and tumor suppressor genes, the 
differentiated thyroid follicle can give rise to well-differentiated papillary or follicular carcinomas, poorly 
differentiated carcinoma, and anaplastic carcinoma. Adapted from [11]
Numerous genetic alterations that have a fondamental role in the pathogenesis of thyroid cancer 
have been identified. The most frequent point mutation is BRAF T1799A which results in the 
constitutional active protein BRAFV600E; it occours in half of the PTCs and it's associated with 
poor clinico-pathological outcomes [13-16]. RAS isoforms activating mutations play a consistent 
role in FTCs pathogenesis although additional genetic alterations are required for cancer 
development [10, 17]. PTEN deletions results in PI3K-AKT pathway activation and are primarly 
responsible of FTCs development. PI3CA, CTNNB1 and p53 mutations are mainly responsible 
of thyroid cancer progression toward less differentiated and most aggressive histotypes [10]. 
In addition to point mutation, copy number gains are common for genes encoding RTKs and 
PI3K-AKT family members; they are prevalent in PDTC and ATC, suggesting a predominant 
role in progression of thyroid cancers [10, 17]. The most frequent oncogenic rearrangement in 
thyroid cancer is RET-PTC, which can occur in PTC [10, 18]. Another important rearrangement 
is PAX8-PPARG, often found in FTC [10]. 
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Mutations
Primary 
signalling 
pathways 
affected
Functional impact on the protein and tumor
BRAFV600E MAPK Activating; promoting tumorigenesis, invasion, metastasis, recurrence and mortality
HRAS, 
KRAS, 
NRAS
MAPK 
PI3K–AKT
Activating; promoting tumorigenesis, invasion and metastasis of PDTC 
and FTC
PTEN 
(mutation) PI3K–AKT
Inactivating the gene but activating the PI3K pathway; promoting 
tumorigenesis and invasiveness
PTEN 
(deletion) PI3K–AKT
Inactivating the gene but activating the PI3K pathway; promoting 
tumorigenesis and invasiveness
PIK3CA PI3K–AKT Activating; promoting tumorigenesis and invasiveness
AKT1 PI3K–AKT Unclear; seems to favour metastasis
CTNNB1 WNT–β-catenin Activating; promoting tumour progression
TP53 p53-coupled pathways Inactivating; promoting tumour progression
IDH1
IDH1-associated 
metabolic 
pathways
Inactivating; impact on tumours is unclear
Table 2. Principal mutations in thyroid cancer.
Fig 6. Principal mutations in thyroid cancer.  A: overall prevalence; B: prevalence in thyroid cancer histological 
types.
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Almost all the mutations involved in thyroid cancer insorgence influence mainly two 
intracellular signalling pathways, MAPK and PI3K-AKT.
The MAPK pathway play a fundamental role in the regulation of cell proliferation and survival 
and it is mainly involved in PTC tumorigenesis; mutations in RAS and BRAF result in 
constitutional activation of this pathway and confer tranformed cell growth advantage. 
Carcinogenesis often implies a wide range of secondary molecular alterations that amplify the 
oncogenic activity of primary ones.
PI3K-AKT pathway plays a fundamental role in FTC evolution as well as in the acquisition of 
metastatic potential; hyperactivation is mainly due to PTEN deletions and PIK3CA and AKT 
copy gain.
The signalling pathways involved in progression toward undifferentiated types are mainly WNT-
b-catenin and p53; aberrant activation of WNT signalling can be a direct consequence of PI3K-
AKT pathway hyperactivation or result from mutations in CTNNB1 gene.
1.3 THYROID CANCER: CONVENTIONAL THERAPIES AND NEW 
DRUGS
In general, treatment of DTC consists of three strategies, depending on disease extent:
• thyroid surgery with or without neck dissection; 
• treatment with radioactive iodine (131I);
• thyrotropin (TSH) suppression by levothyroxine to avoid growth stimulation of 
remaining thyroid cells by TSH.
These approaches achieved a 10-year disease-free survival in more than 90% of the cases, with a 
complete remission in 60% of the patients with local recurrence and in 30% of the patients with 
distant metastases. The overall prognosis of thyroid cancer is excellent; however, overall survival 
falls dramatically when standard therapies fail and the 5-year survival rate decreases to less than 
50% when radioactive iodine therapy loses its activity due to loss of cellular differentiation [19-
20]. 
Current treatment for PDTC and ATC is regarded as almost ineffective and patients with ATC 
show the worst prognosis. The median survival is about 3–4 months and the 5-year survival rate 
is approximately 10%, somewhat better in localized and worse in metastatic disease [20]. The 
8
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sudden onset and evolution of ATC necessitates immediate involvement by surgeons, radiation 
oncologists, medical oncologists, and palliative care teams. Chemotherapy is often added 
concurrently with radiation but in most studies it appears to have a limited effect on survival [20-
22].
Cytotoxic therapy
For patients with PDTCs, ATCs or metastatic DTCs that progress despite these standard 
therapies, systemic chemotherapy has traditionally been a limited option [23]. 
Bleomycin was the first drug used in thyroid cancer treatment; contrasting results and long-term 
toxicities led to gradual abandon [23-24]. Doxorubicin has shown partial response and disease 
stabilization in large cohort studies with best response in patients with lung metastases and high 
performance status [25]. Platinum compounds were able to induce minor clinical responses and 
symptomatic palliation with various degrees of adverse events [23]. 
Due to limited efficacy of monotherapy, different combined treatment have been explored; best 
outcomes are usually obtained when doxorubicin is included.
New molecules
Among the new drugs, proteasome and Aurora kinase inhibitors were demonstrated to be 
effective in both preclinical and clinical investigations [26]. Bortezomib is a proteasome 
inhibitor that has been shown to induce apoptosis and necrosis in relapsing thyroid tumors; 
Aurora Kinase Inhibitors exert proapoptotic and antiproliferative effects through impairment of 
chromosome segregation during the mitotic phase of the cell cycle. There is new evidence that 
proteasome and aurora kinase ihibitors can synergize and exert relevant antitumoral activity in 
thyroid neoplasia [22]. 
Histone deacetylase inhibitors (HDACs) are a promising class of antineoplastic agents that 
induce differentiation and apoptosis. Moreover, they may enhance the cytotoxicity of DNA-
targeting drugs through hyperacetylation of histones [21].
Targeted therapy
In last years there has been large evidence that, among several aberrant molecular mechanisms, 
one specific oncogene or a particular pathway may be sufficient to maintain the malignant 
phenotype, a mechanism defined as 'oncogene addiction'. Inhibition of cancer growth and/or 
apoptosis acting on these pathways is the rationale for targeted therapy [27-28]. 
9
INTRODUCTION
Among all the alterations involved in thyroid cancer development, MAPK and the PI3K-AKT 
signaling pathways are the most exploited for targeted therapy; moreover,  most of them act 
against TK receptors involved in angiogenesis thus having  a good potential in well vascularized 
thyroid carcinomas [29]. 
Nevertheless, taking into consideration the rapid process of tumor progression and adaptation, 
interfering with oncogenic alterations might not be sufficient in the majority of tumors and 
combination therapies to block multiple pathways may be necessary [30].
Antisense drugs, monoclonal antibodies and small-molecule drugs are examples of therapies 
intercepting important molecules in oncogenic pathways. 
Antisense drugs are small synthetic single-stranded DNA sequences of 13-25 oligonucleotides 
complementary to a particular targeted mRNA. When hybridised to the corresponding mRNA, 
RNAse H recognizes the complex and cleaves the mRNA, leaving the antisense drug intact. 
These substances also interfere with ribosomal assembly, blocking gene expression and 
inhibiting protein synthesis. Systemic treatment with antisense drugs is generally well tolerated 
[31].
Side effects are dose-dependent and include thrombocytopenia, hypotension, fever, complement 
activation, prolonged partial thromboplastin time, asthenia, and increased concentration of 
hepatic enzymes [32].
Most small-molecule are kinase inhibitors that obstruct the binding of ATP to the ATP pocket 
within the catalytic domain and thus are known as ATP mimetics. Other compounds target 
regions outside the ATP-binding site of the enzyme, for example the substrate-binding domain. 
These drugs obstruct auto-phosphorylation and signal transduction downstream from the targeted 
kinase [31]. 
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Fig 7. Thyroid cancer molecular pathways and targeted drugs. Represented are most frequent mutated pathways 
in thyroid cancer and levels of action of targeted drugs. Adapted from [29]
Drug Target Mechanism of action
Zactima (ZD6474) RET, VEGFR, EGFR Kinase Inhibitor
Pyrazolopyrimidine (PP1, 
PP2) 
RET, SRC family kinase Kinase Inhibitor
Iodocarbazole (CEP-701, 
-751) 
RET, NTRK Kinase Inhibitor
2-indolinone (RPI-1) RET Kinase Inhibitor
Benzamide (STI571)  RET, ABL, C-KIT, PDGFR Kinase Inhibitor
Sorafenib (BAY43-9006) BRAF, CRAF, VEGFR, RET, PDGFR Kinase Inhibitor
Geldanamycin and derivatives BRAF, CRAF, EGF-R, Her-2, AKT, p53, 
cdk4
Hsp90 inhibitor
Macrolide radicicol and 
derivatives
BRAF, CRAF, EGF-R, Her-2, AKT, p53, 
cdk4
Hsp90 inhibitor
Purine-scaffold derivatives BRAF, CRAF, EGF-R, Her-2, AKT, p53, 
cdk4 
Hsp90 inhibitor
ISIS 5132 CRAF Antisense 
oligonucleotide
Tipifarnib (R115777) RAS Farnesyl transf. inhibitor
L-778123 RAS Farnesyl transf. inhibitor
Lonafarnib (SCH66336) RAS Farnesyl transf. inhibitor
BMS-214662 RAS Farnesyl transf. inhibitor
11
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FTI-277 RAS Farnesyl transf. inhibitor
L744832 RAS Farnesyl transf. inhibitor
ISIS2503 RAS Antisense 
oligonucleotide
CI-1040 (PD184352) MEK1, MEK2 Kinase Inhibitor
PD0325901 MEK1, MEK2 Kinase Inhibitor
ARRY-142886 MEK1, MEK2 Kinase Inhibitor
LY294002 PI3 kinase Kinase Inhibitor
KP372-1 AKT Kinase Inhibitor
CCI-779 mTOR Kinase Inhibitor
RAD001 mTOR Kinase Inhibitor
Vatalenib (PTK787) VEGFR, PDGFR, C-KIT Kinase Inhibitor
AG013736 VEGFR, PDGFR, C-KIT Kinase Inhibitor
NVP-AEE788 VEGFR, EGFR Kinase Inhibitor
Gefitinib (Iressa) EGFR Kinase Inhibitor
Erlotinib (OSI-774) EGFR Kinase Inhibitor
Lapatinib (GW-572016) EGFR, Her-2 Kinase Inhibitor
Canertinib (CI-1033) EGFR, Her-2, Her-3, Her-4 Kinase Inhibitor
Mab 4253 EGFR Antibody
NVP-ADW742 IGF-1R Kinase Inhibitor
PD173074 FGFR4 Kinase Inhibitor
Table 3. Targeted therapy for thyroid cancer. [31]  
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1,9-Pyrazoloanthrone (SP600125) is a chemical compound, derivate of anthrones, that can be 
synthesized by the condensation of 2-chloroanthraquinone with anhydrous hydrazine in pyridine 
at 100 °C. Purification is achieved via conversion to the N-acetyl derivative which is crystallized 
from acetic acid, followed by hydrolysis of the acetyl group with ammonium hydroxide in 
methanol. 
CAS No. 129-56-6
Chemical Name: 1,9-Pyrazoloanthrone
EPA Substance Registry 
System: Anthra[1,9-cd]pyrazol- 6(2H)-one(129-56-6)
Synonyms:
SP600125; JNK INHIBITOR II; SAPK INHIBITOR II;  
Nsc75890; c.i.70300; pyrazolanthrone; 
ANTHRAPYRAZOLONE;
CBNumber: CB6354608
Molecular Formula: C14H8N2O
Formula Weight: 220.23.00
Melting Point: 281~282℃
Storage Temperature: 2-8°C
Solubility: H2O: insoluble
Color: yellow
           Table 4. SP600125 properties
Anthrapyrazoles have been first synthetized in 1984 [33]  in the attempt to find a novel class of 
highly active anticancer DNA-complexing agents with diminished or absent cardiotoxicity 
compared to the anthracycline antitumor antibiotics 
daunorubicin and doxorubicin and anthracenediones. 
In the following years a various amount of 
anthrapyrazoles has been sintesized [34-36] and part 
of them reached phase I and II clinical trials [37-39]. 
In these studies anyway millimolar dosages were 
used to obtain DNA damage activity leading to 
relevant toxic effects. Due to toxicity profile and to 
development of new promising anticancer drugs, 
further studies on SP600125 were not performed.
In 2001 anyway Bennet group reported the inhibitory effect on Jun N-terminal kinase (JNK) by 
14
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different anthrapyrazolones, most powerful of them being SP600125 [40]. It's noteworthy that all 
the subsequent studies were performed with much lower concentrations than DNA-damage 
inducing ones. In the last decades SP600125 was then commercialized and widely used as JNK 
inhibitor, with reported minimal effects on many different kinases. Particular efficacy was shown 
in reducing ischemia-reperfusion injury in different animal models [41-47]. 
Fig. 9 Bennet's syntesized compounds. A: different compounds screened for JNK inhibitory activity and relative 
IC50 values; B:inhibition profiles of SP600125 vs. related MAP kinases (ERK2 and p38–2) and an unrelated serine 
threonine kinase (PKA) performed at Kmlevels of substrates; C: kinase selectivity data for SP600125. Adapted from 
[40].
Despite the general acceptance of SP600125 being mainly a JNK inhibitor, in 2003, in a wide 
range kinase inhibitor specificity screening study, it was shown to be highly specific for many 
different other enzymes [48]. 
Protein Kinase PP1 (10µM)
PP2 
(10µM)
PP3 
(10µM)
SU 6656 
(10µM)
SP 600125 
(10µM)
KT 5823 
(10µM)
EGCG 
(10µM)
ML-7 
(20µM)
ML-9 
(100µM)
MKK1 52±4 55±6 89±8 82±3 89±3 99±3 94±3 102±2 95±3
MAPK2/ERK2 75±1 61±3 92±6 102±6 55±3 106±3 53±6 85±6 101±3
JNK/SAPK1c 98±3 98±1 99±2 103±2 38±5 99±1 76±7 97±3 102±3
SAPK2a/p38 13±1 21±0 100±5 70±7 86±3 102±4 105±5 100±7 94±1
SAPK2b/p38b 22±1 26±0 84±2 90±7 75±1 100±5 87±3 89±3 98±1
SAPK3/p38g 92±5 90±8 83±2 75±5 82±1 103±1 85±4 95±4 98±2
SAPK4/p38d 102±2 96±1 95±2 78±1 98±3 105±6 60±1 75±3 86±3
MAPKAP-K1a 69±6 114±2 115±2 27±6 46±3 105±6 109±0 99±2 44±2
MAPKAP-K2 96±5 106±0 98±2 96±5 72±6 71±5 79±6 93±5 106±7
MSK1 55±2 57±3 93±2 94±6 51±7 74±2 88±0 59±1 14±1
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PRAK 85±7 85±8 97±3 95±2 39±1 83±8 10±2 78±5 91±2
PKA 76±3 74±3 89±5 73±3 82±1 102±5 109±4 85±1 71±4
PKCa 80±3 66±3 100±0 90±4 79±8 102±2 76±1 85±4 80±1
PDK1 97±2 99±3 82±3 94±2 62±5 114±5 50±1 107±6 113±4
PKBa 97±8 77±7 108±1 100±3 95±2 83±2 87±3 88±2 76±1
SGK 94±6 111±1 94±2 70±5 22±7 72±5 104±5 101±0 84±4
S6K1 43±0 70±3 93±3 71±0 22±4 90±4 87±5 74±1 27±3
GSK3b 86±1 113±8 99±0 83±5 60±5 52±1 78±2 107±2 107±5
ROCK-II 65±4 75±4 93±2 43±6 59±3 97±8 53±7 74±1 23±2
AMPK 93±2 84±2 94±2 14±2 26±1 90±2 101±2 82±1 61±1
CHK1 91±4 93±1 96±1 66±5 39±0 93±3 79±2 94±2 103±4
CK2 96±7 90±1 76±7 93±2 63±1 98±5 105±4 83±0 69±1
PHK 70±6 93±4 99±5 21±1 34±1 99±6 78±8 85±3 79±1
LCK 0±0 1±0 77±2 8±4 53±1 94±1 89±6 87±1 116±6
CSK 3±0 3±1 96±7 89±4 71±6 93±1 76±3 94±8 96±4
CDK2/Cyc A 75±4 68±3 84±0 54±7 20±1 94±4 97±0 73±1 75±1
CK1 8±1 6±1 54±1 66±5 10±1 83±1 105±7 106±6 103±4
DYRK1A 101±4 94±4 60±5 23±5 16±6 112±4 9±1 66±8 38±3
Table 5. Inhibition of protein kinases by commercially available inhibitors (% of residual activity); 
Highlighted are kinases on which SP600125 has similar or more efficacy than on JNK. Adapted from [48].
Considering only kinases on which SP600125 has more than 50% inhibitory effect, a functional 
protein interactions network analysis through a dedicated software [49] highlights three main 
areas, all of them involved in cell proliferation.
Fig 10. STRING 9.1 protein protein interaction pathway analysis. A: input kinases; B network expansion and 
clustering [49].
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By these datas it can be seen that SP600125 is able to deeply influence intracellular processes 
with a more complicated mechanism of action than mere JNK inhibition. Moreover effects on 
cell cycle progression have recently been reported [50-53] and SP600125 has been shown to 
influence mitotic spindle organization [54] even if only in last years this effect has been 
attributed to a direct interaction with Mps1 and not to JNK inhibition [55-56].
Fig 11. Stereo view of the inhibitor-binding site in Mps1 and JNK1 with SP600125. Important differences in the 
composition and orientation of key residues are shown. Adapted from [55].
A  turning point was 2012 work by Jemaà et al. in which a drug screening was performed to 
identify compounds selectively killing p53-deficient cancer cells; SP600125 demonstrated to be 
the most selective upon 480 compounds [57].
Fig 12. p53-deficient cells inhibitory activity of screened compounds. Variations in the p53 wt/null cells ratio 
after different drug treatments for 48h compared to the initial 1:1 ratio. SP600125 appears to be the most selective 
one. Adapted from [57]. 
In this study SP600125 was shown to preferentially inhibit p53-null cell growth inducing cell 
cycle perturbations and polyploization. Anyway, the effect on p53-mutated cells were not 
investigated as well as the possible mechanisms of action.
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p53, frequently called the guardian of the genome, is the most often mutated gene in human 
cancers. It is involved in a large amount of signaling pathways that control the cell cycle and 
maintain the integrity of the human genome.  p53 plays a fundamental role in the response to 
cellular stress, acute DNA damage and hyper-proliferative signals caused by oncogene 
expression by inducing apoptosis or cell-cycle arrest and senescence;  it is an important 
safeguard against tumorigenesis preventing the genomic instability and the increased risk for 
carcinogenesis associated with propagation of damaged cells [58-59].
The best characterized molecular 
function of p53 in driving apoptosis, 
cell-cycle arrest, or senescence is as a 
transcriptional factor; in addition it has 
other important non-nuclear activities 
as the ability to repress transcription 
and to promote apoptosis through direct 
interaction with apoptotic regulators in 
the mitochondria and cytosol. Although 
the major part of its targets have clear 
links to apoptosis and cell-cycle arrest, 
some are implicated in other cellular 
processes including metabolism and cell migration, which can also contribute to tumor 
suppression [60].
Human p53 is a nuclear phosphoprotein of 53 kDa, encoded by a 20 Kb gene containing 11 
exons and 10 introns which is located on the small arm of chromosome 17 [61-62]. It consists of 
393 amino acids assembled into five structurally and functionally different domains: an acidic N-
terminal region which contains the transactivation domain (amino acids 1-42), a hydrophobic, 
proline-rich  region  (amino  acids  64-92),  a  central  sequence-specific  DNA-binding  domain 
(amino  acids  102-292),  a  tetramerization  domain  (amino  acids  324-355),  a  highly  basic  C-
terminal region regulatory domain (amino acids 363-393) with a nuclear localization signal and 3 
nuclear  export  signal  sequences.  Of  all  p53  domains,  the  DNA-binding  one  is  the  most 
frequently mutated in human cancers.
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Fig 13. p53 responses to different stimuli.  In response to a wide 
variety of noxious stimuli p53 is able to trigger different cellular 
responses depending on the intensity and duration of the stimulus 
itself.
INTRODUCTION
Fig 14. p53 structure. A: p53 structure and point mutation incidence in human cancers; B: p53 homotetramer 
interacting with DNA. TAD  transactivation domain, PRR proline rich region, OD omotetramerization domain, CTD 
C-terminal domain. Adapted from [63].
3.1 P53 REGULATION
Under normal circumstances, wild type p53 is maintained 
at  very  low  concentrations  within  the  cells;   it  exists 
mainly in an inactive latent form with half-life limited to 
minutes;  anyway cellular  stresses  or  exposure to  DNA 
damaging agents can prolong it to hours.
p53 activity  and stability  are  tightly  regulated  through 
complex  networks  of  post-translational  modifications, 
including  phosphorylation,  acetylation,  ADP-
ribosylation,  ubiquitylation,  sumoylation,  neddylation, 
and  cytoplasmic  sequestration.   Most  of  these 
modifications occur in the N- and C-terminal regions. 
Post-translational  modifications  generally  result  in 
nuclear  translocation  and  stabilization  of  p53,  where, 
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Fig 15. p53 regulation. Different post-
translational modification influence p53 
stability through modulation of the 
interaction with MDM2.
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after activation, it interacts with its target genes. The transcriptional activation leads to diverse 
cellular  responses such as apoptosis,  cell-cycle  arrest  or DNA repair.  Activated p53 also act 
outside of the nucleus to induce apoptosis by binding with anti-apoptotic proteins such as BCL2. 
Phosphorylation  and  acetylation  are  the  main  modifications  enhancing  the  transcription 
activating ability of p53 because they generally result in p53 stabilization and accumulation in 
the nucleus; they also prevent p53 from being targeted for degradation [64].
Phosphorylation  of  p53  generally  results  an increase  in  its  sequence-specific  DNA binding. 
Many protein kinases have been shown to act on p53. Different protein kinases phosphorylate 
several sites on p53, and in some instances the same site can be phosphorylated by more than one 
protein kinase.  Twenty serine and threonine sites have been identified to be phosphorylated in 
human cells; these include serines 6, 9, 15, 20, 33, 37 and 46 and Thr18 and Thr81 in the amino-
terminal region; Ser315 and Ser392 in the C-terminal domain; and Thr150, Thr155 and Ser149 
in  the  central  core.  In  addition,  Thr55,  Ser376  and  Ser378  seem  to  be  constitutively 
phosphorylated in unstressed cells [64-65] . 
Variations  in  p53  phosphorylation  are  physiologically  found  in  cell  cycle  progression: 
phosphorylation of serines 9, 15, 20 and 372 peaks during G1, whereas phosphorylation of Ser37 
and Ser392 peaks during G2/M phase. Ser37 is the only site phosphorylated during S phase and 
acetylation of p53 is highest at G0 [66].
Acetylation also have a  crucial  role  in stabilization transcriptional activation of p53. Almost 
every type of cellular stress increases acetylation levels of several lysines, all of them located in 
the  C-terminal  region,  in  the  regulatory  domains  adjacent  to  the  tetramerization  domain, 
including  Lys305,  Lys320,  Lys372,  Lys373,  Lys381,  Lys382,  and  Lys386.  Two  histone 
acetyltransferases (HATs) are known to acetylate p53: p300/CBP acetylates the C terminus of 
p53 at  Lys305,  Lys372,  Lys373,  Lys381,  and Lys382,  whereas  PCAF (p300/CBP-associated 
factor) acetylates Lys320. The consensus is that the recruitment of the co-activators CBP and 
p300 stabilizes p53 and increase the  sequence-specific DNA binding following DNA damage, 
possibly as a result of an acetylation-induced conformational changes [67-68].
Acetylation may also regulate the stability of p53 by inhibiting its ubiquitylation induced by 
MDM2. Inhibition of p53 deacetylation leads to a longer half-life of endogenous p53 suggesting 
that acetylation of p53 may also contribute to p53 stabilization [67].
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Fig 16. p53 post-translational modifications, enzymes and interacting proteins. TAD transactivation damain, 
TET tetramerization domain, REG regulatory domain; P, phosphorylation; Ac, acetylation; G, glycosylation; Me, 
mono(1) or di-(2) methylation, N8, neddylation; Ub, ubiquitination; polyADP-R, poly-ADP-ribosylation. Adapted 
from [69]
p53 is degraded through an ubiquitin-dependent process primarily mediated by MDM2. The p53 
protein regulates the MDM2 gene at the level of transcription, and the MDM2 protein regulates 
the p53 protein at the level of its activity. This creates a feedback loop that regulates both the 
activity of  the  p53 protein  and the  levels  of  MDM2.   MDM2 seems to  have  roles  in  both 
localization and degradation of p53. Recent data indicate that monoubiquitylation might act as a 
signal in nuclear export for p53 and that different levels of MDM2 can induce both mono and 
polyubiquitylation in a dose-dependent manner, so determining the fate of p53 [64].
MDM2 is also regulated by ATM, a protein that has a key role in the cellular response to DNA 
damage. ATM is normally rapidly activated by DNA damage and can phosphorylate MDM2, 
resulting in MDM2 deactivation, which leads to increased p53 levels.
As well as ATM, MDM2 is also regulated by ARF; ARF might facilitate accumulation of p53 by 
binding  to  MDM2 and  inhibiting  its  association  with  p53  or  by promoting  sumoylation  of 
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MDM2.  Recent  evidence  indicates  that  this  and  the  MDM2  pathways  are  structured  very 
differently in normal cells versus stressed cells: in normal, unstressed cells, MDM2 levels are 
independent of p53 activity as a transcription factor, but this feedback pathway becomes active 
under stress. A relative of MDM2, MDMX, is also a key negative regulator of p53 and is also 
upregulated  in  many  tumours  that  express  wild-type  p53,  providing  still  another  potential 
mechanism for deactivating p53.
Fig 17. p53-MDM2 interactions. p53 and MDM2 form an auto-regulatory feedback loop. p53 stimulates the 
expression of MDM2; MDM2 inhibits p53 activity because it blocks its transcriptional activity, favours its nuclear 
export and stimulates its degradation.
In addition to this pathways, p53 is negatively regulated by several other proteins. JNK was one 
of the first MDM2-independent p53 degradation pathways to be identified and actually seems to 
have a dual role: under unstressed conditions, JNK binds to p53 preferentially in the G0/G1cell-
cycle  phase  resulting  in  ubiquitylation  and  degradation  while  under  stress  conditions  JNK 
phosphorylates p53 at threonine 81, resulting in stabilization and activation [70-71].
Other proteins that act as E3 ligases to promote p53 degradation include PIRH2, which is a p53 
target gene, COP1 protein and TAF1 [72-74].
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3.2 p53 EFFECTS: CELL CYCLE ARREST, MITOTIC CATASTROPHE 
OR  APOPTOSIS?
It is known that DNA-damaging stimuli and stressful environmental conditions lead to either 
growth arrest or cell death. p53 responds in various modes, depending on several factors; the 
most important ones are cell type, growth factors avalaibility, stress duration and intensity .  
The classical view implies that low levels of p53 induce cell cycle arrest, whereas high levels of 
p53 induce apoptosis. This way of action is usually explained with the fact that p53 binds to 
proarrest genes with high affinities but associates with proapoptotic genes with low affinities. 
It has been recently reported that p53 levels can vary in a series of discrete pulses, the number of 
p53 pulses being positively related to the amount of DNA damage. The p53-Mdm2 negative 
feedback loop is  recognized as the basis of p53 oscillation,  and additional positive feedback 
loops may make p53 oscillations more robust. On the contrary, it was suggested that the p53-
PTEN-Akt-MDM2 positive  feedback loop may terminate  oscillations  by disrupting  the  p53-
MDM2 loop.  The  strength  of  DNA damage  is  repeatedly  evaluated;  the  cell  survives  after 
transient  p53 pulses,  or  apoptosis  is  induced by sustained p53 pulses.  This  may represent  a 
reliable and flexible mechanism [75].
p53 and cell cycle.
The best characterized antiproliferative effect of p53 is its role in G1 phase arrest of cell cycle. 
p53 is required for DNA damage-induced G1 arrest primarily through transactivation of p21, a 
cyclin-dependent kinase inhibitor. When levels increase p21 binds and inactivates cyclin E/Cdk2 
or  cyclinD/Cdk4  complexes  resulting  in  RB 
hypophosphorylation  and  cell  cycle  arrest;  RB  is  a 
negative regulator of the transcription factor E2F, which 
is  required  for  expression  of  S-phase-specific  genes 
[76]. Anyway, there must be other actors implicated in 
p53  effects  because  p21  KO  cells  are  only  partially 
defective in DNA-damage induced growth arrest while 
p53 deficiency totally abolishes it [77-79].
In addition to this early checkpoint, p53 also regulates 
the maintenance or sustained G2/M arrest. In this case, 
24
Fig 18. p53 and cell cycle regulation. Cell 
cycle checkpoint and correlated p53 actions.
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rather than mediated by p21, which has little CDK1 inhibitory capacity, other p53 targets  may 
act as effectors that inhibit the activation of Cdc2. Cdc2 is inhibited simultaneously by three 
transcriptional  targets  of  p53,  GADD45,  p21 and 14-3-3.  Binding of  Cdc2 to  Cyclin  B1 is 
required for its activity, and repression of the Cyclin B1 gene by p53 also contributes to blocking 
entry into mitosis. p53 also represses Cdc2 gene, to help ensure that cells do not escape from the 
initial block [79-81].
p53 and senescence
Cellular senescence is a permanent cell cycle arrest that ocours in response to different stimuli,  
including telomere dysfunction, oncogene activation, and DNA damage. Senescent cells display 
several characteristic morphological and biochemical features: they have a much larger flattened 
cytoplasm that contain many vacuoles and cytoplasmic filaments, a bigger nucleus and nucleoli 
and are sometimes multinucleated;  in  some cases,  senescent  cells  display an increase in  the 
number of lysosomes and a prominent golgi. They often become resistant to cell-death signals, 
like apoptosis, and they acquire widespread changes in gene expression 
It has been shown that the p53 levels were increased in senescent cells; overexpression of p53 is 
sufficient to induce premature senescence in p53-null  cells  while inactivation or loss of p53 
results  in an extension of  cell  lifespan.Moreover  it  has  recently been demonstrated that  p53 
restoration induces premature senescence and tumor regression [82-84].
Senescence  is  usually  triggered   by  p53  or  by  p16/pRB  pathways:  active  p53  induces  the 
expression  of  p21  that,  among  other  activities,  suppresses  the  phosphorylation  and  the 
inactivation of pRB. Anyway, although p21 contributes to the growth arrest of senescent cells, it 
is  unlikely  to  be  solely  responsible  for  the  complex  changes  that  characterize  senescence. 
Senescence  signals  that  engage  the  p16–pRB  pathway  generally  do  so  by  inducing  the 
expression of p16, another CDK inhibitor that prevents pRB phosphorylation and inactivation. 
Moreover there is reciprocal regulation by these pathways [84-85] .
p53 and mitotic catastrophe
In addition to cell cycle arrest in response to DNA damage, p53 plays a fondamental role in G1 
arrest following alterations in spindle pole organization and chromosomes segregation. In this 
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case p53 activation causes a definitive arrest at a tetraploid G1 state. There is a broad consensus 
that p53-deficient cells that are in the tetraploid G1 state are not prevented from reentering the 
cell  cycle  to  reduplicate  their  DNA  unchecked,  leading  to  polyploidy  and  subsequent 
chromosomal instability with subsequent propagation of errors of late mitosis and the generation 
of aneuploidy [86]. 
Importantly, the loss of p53 can sensitize cells to microtubule poisons such as paclitaxel due to 
its capacity of inactivating the polyploidy checkpoint. After treatment with spindle inhibitors, 
cells possessing an intact p53 system undergo G1 arrest and thus are resistant to antimicrotubule 
agents. Cells deficient for p53 fail to undergo such a G1 arrest and endoreduplicate their DNA, 
leading to massive cell death by a definite mechanism called mitotic catastrophe [86-88]. 
Mitotic catastrophe is defined as “a cell death mode occurring either during or shortly after a 
dysregulated/failed  mitosis  and  can  be  accompanied  by  morphological  alterations  including 
micronucleation  (which  often  results  from chromosomes  and/or  chromosome fragments  that 
have not been distributed evenly between daughter nuclei) and multinucleation (the presence of 
two or more nuclei  with similar or heterogeneous sizes, deriving from a deficient separation 
during cytokinesis). However, there is no broad consensus on the use of this term, and mitotic 
catastrophe can lead either to an apoptotic morphology or to necrosis” [89]. 
A group of various stimuli and perturbations can trigger mitotic catastrophe. Some inducers of 
mitotic  catastrophe  directly  affect  the  integrity  of  the  genetic  material  (for  example,  DNA-
damaging agents), whereas others interfere with the complex molecular machinery that ensures 
the correct   segregation of chromosomes (for  example,  microtubular  poisons).  Finally,  some 
compounds trigger mitotic catastrophe via uncharacterized signalling pathways [90]. 
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Fig 19. Mitotic catastrophe mechanisms. 1: In response to DNA damage or mitotic altertations cells arrest in 
mitosis and usually undergo the mitotic death programme. 2-4: mitosis-incompetent cells can escape the mitotic 
arrest, either by slipping into the interphase or by undergoing one round of aberrant mitosis that often cannot be 
completed resulting in cytokinesis failureand generation of tetraploid cell. 5: most of tetraploid cells die or become 
senescent. 6: completion of aberrant division results in aneuploid cells owing to gross chromosomal rearrangements 
that result in cell death of growth arrest. 7-9:  In rare cases these aneuploids survive but undergo the mitotic death 
programme, mitotic slippage or another round of aberrant mitosis. 10-14: in some instances, tetraploid cells 
proliferate giving rise to multipolar divisions, succumb to mitotic catastrophe-initiated mitotic death, undergo 
mitotic slippage or undertake aberrant divisions, leading to the generation of potentially tumorigenic aneuploid 
daughter cells. Adapted from [90].
p53 and apoptosis
In large part, the potent anti-cancer activity of p53 has been linked to the intrinsic mitochondria-
mediated pathway of apoptosis. As a transcription factor, p53 induces several pro-apoptotic Bcl-
2 family  members including Bax, Puma, Noxa and Bid, and represses the transcription of some 
anti-apoptotic factors, including Bcl-2, Bcl-xL and survivin. In addition to its complex functions 
as  a  nuclear  transcription  factor,  p53  can  act  in  the  cytosol  and  mitochondria  to  promote 
apoptosis through transcription-independent mechanisms [91-93].
The hallmark of the transcriptionally independent p53-mediated apoptosis is the stress-induced 
accumulation of p53 in the cytosol and in the mitochondria that leads to interactions with several  
members  of  the  Bcl-2 family.  Binding of  p53 to  Bak in  the  outer  mitochondrial  membrane 
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catalyses Bak activation; for this process acetylation of p53 at lysine 120 seems to be important. 
Moreover,  activation of Bax correlates also with cytosolic accumulation of p53; in this case 
instead of the central DNA-binding domain that binds to Bak, Bcl-2 and Bcl-xL, the N-terminus 
of p53 and in particular its proline-rich domain is indispensable for direct activation of Bax. Both 
Bak and Bax activation lead to cytochrome c release [94-95].
In addition p53 is able  to interact with Bad, another pro-apoptotic Bcl-2 family member. The 
formation of a p53–Bad complex  leads to cytosolic and mitochondrial accumulation, thereby 
facilitating its function in directly activating Bax or Bak [96].
Regulation  of  p53  nuclear  export  and  abundance  in  the  cytosol  and  mitochondria  is  the 
fundamental way to controll its transcription-independent pro-apoptotic activity. As long as p53 
is preferentially accumulated in the nucleus, large amounts of protein are required for cytosolic 
localization.  Moreover, the accumulation of large amounts of non-nuclear p53 can also be the 
result  of  specific  localisation  signals,  such  as  posttranslational  p53  modifications  or  the 
interaction  with  nuclear  export  factors.  Among  the  posttranslational  modifications  of  p53, 
ubiquitylation appears to have a prominent role as mono-ubiquitylation is a signal for nuclear 
export while only polyubiquitylation targets p53 for proteasomal degradation [93, 97].
Fig 20. p53 and mitochondrial apoptosis induction. p53-dependent apoptosis can be trascription-dependent 
through the induction of Bax and PUMA or trascription-independent,  including direct effects on Bax and Bcl-xL. 
While in the first case nuclear translocation and post-traslational modifications are required, in the second one the 
cytoplasmatic pool of p53 acts direcly through protein-protein interactions.  Adapted from [98]
3.3 P53 AND THYROID CANCER
At variance with other human malignancies, p53 point mutations are not frequent in thyroid 
cancer while  functional  inactivation by a variety of different  mechanisms is  apparently very 
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common; the principal alterations are related to the complex network of p53 family member 
isoforms and include the expression of proteins with dominant negative function, malfunction or 
overexpression of regulatory proteins. For these reasons the prevalence of p53 mutations in well-
differentiated thyroid carcinoma ranges from 0% to 25% while p53 protein overexpression has 
been reported as 11% to 59%. p53 indirect inactivation may be an important prerequisite for 
early  phases  of  thyroid  cell  transformation  while  p53  mutations  have  been  implicated  as  a 
transitional step between well-differentiated thyroid carcinoma and anaplastic carcinoma, as P53 
alterations have been reported in more than 60% of ATCs [99-101]. Moreover p53 inactivation 
plays a fundamental role in tumor aggressiveness, metastatic behaviour and  chemoresistance 
acquisition;  several  reports  indicate  that  wild-type  p53 gene  delivery into  anaplastic  thyroid 
cancer cells induces a partial differentiation, with the re-expression of thyroid specific-genes, and 
makes cells more vulnerable to the effect of chemotherapy. This effect may be increased by the 
concomitant use of histone deacetylase inhibitors, which stimulate p53 acetylation and functional 
activation  [99, 102-104] . 
Fig 21. p53 mutation and activity. Graphical elaboration of  mutation effect and their residual transactivation 
activity in total human cancers and in thyroid cancer. As it can be seen in undifferentiated thyroid cancers p53 
mutations result in total loss of p53 transactivational activity. Statistical data from [105], database version R17, 
November 2013 .
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Microtubules  are  essential  components  of  the  cytoskeleton  that  play  a  major  role  in  many 
cellular functions; in most cells, cytosolic microtubules are involved in intracellular transport, 
organelle positioning, cell shape and motility. They control differentiative processes involving 
intracellular  rearrangements  and  changes  in  morphology.  Last  but  not  least,  they  form two 
essential structures in dividing cells: the mitotic spindle and the midbody [106-107]. 
Microtubules are hollow tubular structures with an external diameter of 25 nm, constituted of 
heterodimers  of  α  and  β  tubulin;  lateral  and  longitudinal  interactions  between  the  tubulin 
subunits are responsible for maintaining the tubular form. Longitudinal contacts between the 
ends of  adjacent  subunits  link the subunits  head to  tail  into a  linear  protofilament. Through 
lateral interactions, protofilaments associate side by side into a sheet or cylinder. 
In most cells, they originate in the perinuclear region, at the  Microtubule Organizing Center 
(MTOC)  that  is  formed by two centrioles  surrounded  by peri-centriolar  material  containing 
proteins implicated in microtubule nucleation and organization. Microtubules are thus polarized 
with a minus-end capped and anchored at the MTOC and a plus-end generally localized at the 
periphery  of  the  cell.  The  plus-ends  explore  the  cytoplasm  in  a  very  dynamic  manner: 
microtubules undergo phases of growth, pause and shrinkage, separated by rescue (transition 
from shrinkage to growth phase) or catastrophe (transition from growth phase to shrinkage) [106, 
108].
Polymerization and depolymerization of microtubules is driven by the binding, hydrolysis and 
exchange of a guanine nucleotide on the β-tubulin monomer; GTP hydrolysis  is not directly 
involved in microtubule assembly but is necessary for switching between catastrophe and rescue.
Polymerization is typically initiated from a pool of GTP-loaded tubulin subunits. GTP hydrolysis 
occurs shortly after subunit incorporation and it has been postulated that this process changes the 
conformation of a protofilament from a slightly curved tubulin-GTP to a more profoundly curved 
tubulin-GDP structure. This nucleotide dependent conformational model predicts that the curved 
tubulin-GDP is  forced  to  remain  straight  when  it  is  part  of  the  microtubule  wall.  Growing 
microtubule sheets are thus believed to maintain a ‘cap’ of tubulin-GTP subunits to stabilize the 
straight  tubulin  conformation  within  the  microtubule  lattice.  Closure  of  the  terminal  sheet 
structure  generates  a  metastable,  blunt-ended  microtubule  intermediate,  which  might  pause, 
undergo further  growth or  switch to  the depolymerization phase.  A shrinking microtubule is 
characterized  by  fountain-like  arrays  of  protofilament  structures,  a   conformational  change 
driven by tubulin-GDP that  destabilize lateral  contacts between adjacent  protofilaments.  The 
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polymerization–depolymerization cycle  is  completed by exchanging GDP of  the disassembly 
products with GTP [109].
Microtubule dynamics are precisely regulated through intrinsic processes such as the presence of 
a  plus-end  GTP-cap  and  through  extrinsic  processes,  mostly  due  to  the  interaction  with 
microtubule associated proteins (MAPs).
Fig 22. Microtubules structure and dynamic. Polymerization is typically initiated from a pool of GTP-loaded 
tubulin subunits. Growing microtubule ends fluctuate between slightly bent and straight protofilament sheets and its 
closure generates a metastable, blunt-ended microtubule intermediate, which might pause, undergo further growth or 
switch to the depolymerization phase. The polymerization–depolymerization cycle is completed by exchanging GDP 
of the disassembly products with GTP. Adapted from [109]
4.1 MICROTUBULES ASSOCIATED PROTEINS
Microtubule  dynamics  and  function  are  modulated  by  interactions  with  other  proteins, 
microtubule motor proteins and non-motor microtubule associated proteins (MAPs). 
The two major families of microtubule motors are the  kinesins and  dyneins.  Motor proteins 
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generate  force  upon  interaction  with  microtubules  and  these  forces  are  used  for  various 
intracellular functions, most obviously intracellular transport. Microtubule dependent transport 
takes place in almost all cell types, serving diverse functions. Moreover, other kinesin motors 
catalyse  the  depolymerization of  microtubules,  thus  participating in  the complex network  of 
interacting proteins that regulate microtubule dynamics [107, 110-113]. 
The heterogeneous group of non-motor MAPs comprises not only many proteins that stabilize 
microtubules but also severing proteins which destabilize the microtubule network [113]. 
Fig 23:Mechanisms of microtubules plus-end tracking.  +TIPs can arrive at the microtubule tips by diffusion in 
the cytoplasm or along the microtubule lattice. Alternatively, they can also be transported to microtubule plus ends 
by kinesins.  +TIPs  that  recognize  a  specific  structure  at  the  growing microtubule  end  (or  co-polymerize  with 
tubulin) might be immobilized at  the ends until  this structure is  converted into the regular  microtubule lattice.  
Adapted from [109]. 
Another important group of MAPs is constituted by plus end-tracking proteins (+TIPs), which 
help to control microtubule dynamics and interactions with cellular organelles and subcellular 
domains, thus coordinating complex aspects of cell architecture. Most +TIPs bind to growing 
microtubule plus ends because of the presence of the GTP-cap and specific sites exposed only on 
protofilaments [109, 114]. +TIPs can either recognize growing plus ends or co-polymerize with 
tubulin; individual +TIPs are not able to move on microtubules but are transiently immobilized 
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at  the growing end.  Anyway,  association with microtubule-binding partners such as kinesins 
might  be  sufficient  to  target  some  proteins  to  microtubule  ends  through  ‘hitchhiking’,  a 
mechanism that is common for many +TIPs. Dissociation of +TIPs from microtubule ends can 
occur  spontaneously  or  can  be  driven  by  structural  changes  in  the  microtubule  lattice,  a 
mechanism known as treadmilling [109, 115-117].
An important function of +TIPs is to attach and stabilize microtubule ends at the cell cortex, 
either by linking microtubule ends directly to actin or to cortically bound factors. +TIPs can 
stabilize microtubules independently of each other, but can also function cooperatively. Because 
microtubules act as ‘rails’ for transport, selective microtubule attachment and stabilization, they 
can help to establish targeted delivery of vesicles and macromolecules to cellular subdomains, 
such as leading cell edges, intercellular junctions or growing cell ends. In addition, +TIPs can 
also link microtubule ends to intracellular membranes [109].
4.2 MICROTUBULES MODIFICATIONS
Many tubulin  post-translational  modifications  are  known:  detyrosination  and  the  related  D2 
modification, glutamylation, glycylation, acetylation, phosphorylation and palmitoylation. Most 
of them occur on tubulin subunits after polymerization into microtubules with the exception of 
phosphorylation  on serine residue S172 of  b-tubulin by the Cdk1 kinase  that  occurs  on the 
unpolymerized tubulin dimer and inhibits its incorporation into assembling microtubules. It has 
long been known that stable microtubules, as compared to dynamic microtubules, accumulate 
more modifications and these modifications play specific role as differences in tubulin patterns 
can be seen between stable microtubules [118-120].
Detyrosination involves the removal of C-terminal tyrosine of a-tubulin in microtubule polymers 
by an unidentified carboxypeptidase wich is  related to Nna1/CCP1. The reverse tyrosination 
reaction  occurs  on  soluble  tubulin  heterodimers  and  is  catalyzed  by tubulin  tyrosine  ligase 
(TTL). Detyrosinated a-tubulin may undergo a second proteolysis,  Δ2 PTM, that removes the 
terminal  glutamic  acid  residue.  The  Δ2  a-tubulin  that  is  released  from microtubules  during 
depolymerization cannot revert to an unmodified state, thus limiting the amount of a-tubulin that 
undergoes recycling [121-124].
The detyrosination/tyrosination  cycle  differentially recruits  two types  of  microtubule-binding 
proteins, molecular motors and plus-end tracking proteins (+TIPs). For example motor protein 
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Kinesin-1  binds  preferentially  to  detyrosinated  microtubules  rather  than  tyrosinated 
microtubules;  this  could  enable  Kinesin-1  to  preferentially  move  various  cargoes  along 
detyrosinated microtubules [125-127].  
Proper functioning of the detyrosination/tyrosination cycle has also been shown to influence 
tumorigenesis. Multiple studies have shown that TTL is downregulated in animal and human 
cancers.  Low  levels  of  TTL  protein  and  tyrosinated  tubulin  correlate  with  increased 
tumorigenisis,  tumor  invasiveness,  and poor  prognosis,  suggesting  that  detyrosinated  tubulin 
provides a growth advantage [128-130].
Glutamylation and glycylation involve the addition of variable numbers of glutamate or glycine 
residues onto the C-terminal tails (CTTs) of both a- and b-tubulin. Glycylation is mainly limited 
to tubulin incorporated into axonemes of cilia and flagella whereas glutamylation is prevalent in 
neuronal cells, centrioles, and the mitotic spindle. Both modifications have been found on the 
same tubulin CTT and there is cross-talk between the a- and b-tubulin tails regulating the type 
and level of each modification [119, 131]. Recent work has shown that polymodifications of the 
tubulin  CTTs  could  mark  specific  microtubules  for  severing  and  thus  influence  polymer 
dynamics and density. Mutations of the b-tubulin polymodification sites resulted in an inability 
of cells to complete cytokinesis in a similar way to  loss of the severing proteins [132-133].
The tubulin glutamylases belong to a family of enzymes that contain a tubulin tyrosine ligase-
like  (TTLL)  domain.  Eight  mammalian  TTLL domain-containing  proteins  are  known  to  be 
tubulin glutamylases that differ in their specificity for a- or b-tubulin and in preferential chain-
initiating or chain-elongating activity  [134]. Both glycylation and glutamylation are reversible 
reactions, however the pathways responsible for the reverse reaction are still  not clarified; a 
recent study identifies the carboxypeptidase CCP5 as the tubulin deglutamylase but it has not yet 
been reported how deregulation of CCP5 affects microtubules dynamics [135]. 
Acetylation is unique among the known tubulin modifications in that it occurs on lysine 40 of a-
tubulin which is postulated to reside on the luminal face of microtubules. It is unclear how the 
enzymes that carry out acetylation/deacetylation would have access to this  site and how this 
luminal modification could influence microtubule-based functions that occur on the cytoplasmic 
face. 
The acetylation appears with a delay after microtubule assembly and is seen as a marker of 
polymer  age.  MEC-17,  a  protein  related  to  GCN5  histone  acetyltransferases  was  recently 
identified as an important a-tubulin acetyltransferase. In animal cells, several acetyltransferases 
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colocalize with acetylated microtubules and some of them (NAT1, NAT10 and ELP3) regulate 
the level of a-tubulin acetylation, but it is not known whether any of these enzymes have direct 
activity on a-tubulin [118, 136]. Deacetylation  is catalyzed by HDAC6 and SIRT2 deacetylases, 
enzymes that are related to histone deacetylases. Knockdown of either HDAC6 or Sirt2 results in 
hyperacetyled tubulin suggesting that the two enzymes may be interdependent [137-139]. 
Fig 24. Microtubules post-translational modification and relative enzymes. The carboxy-terminal tails of both 
tubulins are represented as amino acid sequences. Both α-tubulin and β-tubulin can be modified by 
polyglutamylation and polyglycylation on different Glu residues within those tails. Together with detyrosination at 
the C terminus and the follow-up removal of the penultimate Glu residue (which generates Δ2-tubulin), these 
modifications are specific to the C-terminal tails of tubulin. Acetylation (Ac) of Lys40 is localized at the amino-
terminal domain of α-tubulin.  Adapted from [107].
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 Acetylation of a-tubulin on lysine 40 is very common and can be found on stable microtubules 
in most cell types. Although tubulin acetylation is not necessary for cell and organism survival, 
recent  work  has  suggested  that  a-tubulin  plays  a  positive  role  in  motor-based  trafficking  in 
mammals [140]. As HDAC6 has recently been shown to deacetylate cytosolic proteins other than 
tubulin (e.g. Cortactin, HSP90 and b-catenin) and regulates a variety of other cellular events (e.g. 
aggresome formation,  cell  motility,  ciliary disassembly,  and transcriptional corepression),  the 
role  of  HDAC6/Sirt2  deacetylation of a-tubulin in  regulation of microtubule-based functions 
remain to be clarified.
4.3 MICROTUBULES AND INTRACELLULAR ORGANIZATION
In normal, not-polarized resting cells there is a major asymmetry between the center and the 
periphery established mainly by the microtubule network. Minus-ends of microtubules are in 
general  located  at  the  cell  center,  bound to  a  MTOC while  their  plus-ends  explore  the  cell 
periphery. +TIPs bind to the plus-ends of growing microtubules and participate in the regulation 
of their  dynamics at  the periphery of the cells. In most animal cells  in interphase the major 
MTOC is constituted by the  the centrosome; the centrosomal microtubules spread out in the 
whole cell through the cytoplasm, playing a role in positioning, organization and maintenance of 
different organelles. In some cells the nucleus and the Golgi apparatus can be additional sites of 
microtubule nucleation and influence their own organization with a sub-population of specific 
microtubules [106].
Nuclear positioning depends mostly on centrosomal microtubules and proteins found at  their 
plus-ends, like dynein and dynactin, and the dynein activator complex; these proteins appear to 
interact with cortical proteins to generate forces that regulate nuclear positioning. Centrosomal 
microtubules also interact directly with the nuclear envelop. By the compensation of all these 
forces and connection astral microtubules are able to maintain the nucleus at the center of the 
cell;  some  additional  proteins  are  particularly  important  in  pushing  or  pulling  forces  to 
participate  in  nuclear  positioning:  CLASPs,  found  on  microtubules  of  the  leading  edge  of 
migrating cells, IQGAP1, an actin-binding protein, and APC involved in interactions between 
microtubules plus-ends and the cortex.  [141-142].
Microtubule dynamics play a central role in the positioning and function of organelles involved 
in  intracellular  trafficking:  the  endoplasmic  reticulum  (ER),  the  Golgi  apparatus  and  the 
endosomes/lysosomes.
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ER morphology and movements are essential for its function in protein synthesis and trafficking 
to the Golgi.  In animal cells  kinesin-1 seems to be the major motor protein involved in ER 
positioning and movement. Kinesin-1 is also involved in positioning and motility of ER exit-
sites and participates in ER to Golgi trafficking [143]. Moreover STIM1 is a +TIP that is not a 
cytoplasmic protein but an integral protein of the ER and  play a major role in ER remodeling. It  
also plays a significant role in the regulation of calcium storage as microtubule depolymerization 
is involved in calcium entry at the ER and STIM1 localization and function are necessary for this 
process  [144]. In most mammalian cells, the Golgi apparatus is shaped like a ribbon closely 
associated  with  the  centrosome.  Its  juxta-nuclear  localization  requires  the  presence  of 
microtubules; without them the Golgi apparatus is dispersed in the form of mini-stacks formed at 
ER exit-sites and unable to migrate to the cell center  [145]. Microtubule-dependent molecular 
motors  are  essential  for  Golgi  organization  and in  particular  the  minus  end  directed  motor, 
cytoplasmic dynein and its regulatory proteins. Plus-end directed motors are also involved in 
Golgi organization; a fraction of /kinesin-1 for example is localized at the Golgi and its depletion 
induces the compaction of the Golgi apparatus [146]. Golgi-nucleated microtubules indeed play 
a key role in Golgi organization. This microtubule sub-population is stable and acetylated; upon 
exit from mitosis golgi membranes  specifically stabilize a microtubule subset thatis involved in 
the  organization  of  Golgi  in  the  centrosomal  area.  The  important  role  of  Golgi-derived 
microtubules in the of Golgi apparatus formation and maintenance suggests some organelles are 
not only passively arranged by elements but also actively participate in cellular and cytoskeleton 
organization [147-148].
Fig 25. Microtubules transport and organization of cellular organelles. Microtubules constitute the skeleton by 
which intracellular organelles maintain their position and shape; moreover endosome-lysosome trafficking occours 
on it. Graphical rielaboration of [108].
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Importantly, microtubules are essential for mitochondria positioning and transport. Mitochondria 
transport has been studied especially in axons, in neuronal cells, but also in non-polarized cells 
and it  has been observed that several  motor  proteins transport  mitochondria  as cargos along 
microtubules.  Mitochondrial  tubules  grow and shrink  along with  dynamic microtubules,  and 
immobile mitochondria are captured by plus-ends of growing microtubules [149].
4.4 MICROTUBULES AND CELL MIGRATION.
Migration is a dynamic, cyclical process in which a cell extends a protrusion at its front, the 
leading edge,  that  attaches  to  the  substratum on which  the  cell  is  migrating,  followed by a 
contraction that moves the cell body toward the protrusion, and finally the attachments at the cell 
rear, the trailing edge, release as the cell continues to move forward. 
The main players in this process are actin and myosin, that provide  the forces pushing forward 
the leading edge, endocytic vescicles that allow redistribution of membrane and proteins from 
the trailing edge to the leading edge and the microtubules that reallocate intracellular structures, 
regulates vescicles transport and allow specific enzymes to reach action sites [150-152].
Fig 26. Cell migration. A: in migrating cells the movement is mainly due to pulling and pushing forces generated 
by actomyosin contraction, an event finely regulated by Rho kinase. B: actin and microtubles reorganization confer 
peculiar morphology to cellular structures. 
During cell migration there is constant formation and sequential disruption of adhesive contacts. 
At the leading edge of the cell there are two types of protrusive structures called lamellipodia 
(protrusive  sheet-like  structures  consisting  of  a  cross-linked  meshwork  of  actin-myosin 
filaments)  and  filopodia  (fingerlike  structures  consisting  of  thin  parallel  bundles  of  actin 
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filaments oriented in the direction of protrusion) that form weak sites of attachment called focal 
complexes [150, 153].
at the leading edge as new adhesions form, they can disassemble (adhesion turnover) or stabilize 
and  grow  into  more  mature,  larger  ones.  The  molecular  components  of  stable  and  nascent 
adhesions  are  similar,  although  there  are  molecules  present  only  in  specific  subtypes.  The 
molecular mechanisms underlying the fate of an adhesion are unclear. Rho GTPases are critical 
effectors in this process. They in turn are controlled by signals emanating from adhesion-related 
signalling modules, such as a multi-protein complex that includes FAK, Src, paxillin, Crk, CAS, 
PAK and GIT.
Adhesion that undergo maturation form large focal adhesion complexes which provide robust 
anchorage just behind the leading edge. Actomyosin filament bundles form and insert into it and 
movement is possible via the contractile activity of these filaments and the polymerization of 
actin filaments at the leading edge. 
Actomyosin-based contraction is controlled by the small Rho GTPases Cdc42, Rac and RhoA. 
Regulation by these GTPases is antagonistic. RhoA activates Rho-kinase (also called ROCK), 
which  in  turn  phosphorylates  and  inactivates  the  phosphatase  that  dephosphorylates  MLC, 
resulting  in  increased  contractility.  A similar  mechanism has  been  shown for  Cdc42,  acting 
through MRCK. Conversely,  Rac activates PAK, which phosphorylates and inactivates MLC 
kinase, thus leading to decreased contractility and promoting spreading. However, PAK may also 
phosphorylate MLC directly, which would increase contractility. The predominance of the first 
or  the  second  mechanism  seems  to  be  regulated  by  spatial  considerations  or  differential 
regulation  of  PAK  activity.  Finally,  PAK  regulates  microtubules  through  stathmin 
phosphorylation, which results in decreased microtubule catastrophe  [150, 153-154]. 
Microtubules  partecipate  in  cell  migration  by allowing transport  of  specific  proteind  and of 
endocytic vescicles at the required sites. A local regulation of +TIPs and small GTPases at the 
leading edge is necessary for the establishment of  cell polarization; the most important ones are 
Rho, Rac, and Cdc42 that coordinate assembly and disassembly of actin filaments in response to 
extracellular signals, Rab GTPases that control endocytosis, Src that accumulates at cadherin 
based cell  adhesions  where it  is  responsible  for  reforming and maintaining the strength and 
integrity of established cell-cell contacts, FAK that in concert with Src signaling has been shown 
to be critical for the regulation of adhesion turnover at the leading edge of migrating cells, while 
Glycogen Synthase Kinase 3-beta (GSK3β), Casein Kinase I (CKI) and the scaffolding proteins 
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Axin  and  Adenomatous  Polyposis  Coli  (APC)  regulate  β-catenin  and  intercellular  adhesion 
[153].
Fig  27. Differences in resting and migrating cells.   A: in a non-polarized cell the most important  polarity is 
established by the  asymmetry between the center and the periphery of the cell. B: strong cellular  polarization, as 
observed during migration, imposes an additional axis, a front and a rear of the cell being differentiated in addition  
to the center and periphery. The reorganization of the MTOC and other organelles during polarization allows the 
formation of the leading edge. Graphical rielaboration of [106].
A very important link between microtubules and cell migration is constituted by the activity of 
HDAC6: this enzyme regulates multiple important biological processes, such as cell migration, 
cell  spreading,  the  degradation  of  misfolded  proteins  and  stress  granule  formation  through 
complexes  with  partner  proteins.  HDAC6-mediated  deacetylation  regulates  microtubules 
dependent cell motility as its inhibition leads to an increased accumulation focal adhesion sites 
and prevents migration. In addition to its interaction with tubulin, HDAC6 is translocated to 
actin-enriched membrane ruffles, where it interacts with the F-actin binding protein cortactin. 
The inhibition of HDAC6 activity results in cortactin hyperacetylation, prevents its translocation 
to the cell periphery, blocks any association with F-actin, and impairs cell motility. By altering 
the ability of cortactin to bind F-actin, HDAC6 also regulates autophagosome-lysosome fusion, 
another important process that regulates cell migration and in particular rear end detachment. 
Moreover HDAC6 regulates β-catenin levels through modulation of proteosomal degradation; b-
catenin  plays  a  fundamental  role  in  linking  cytoskeleton  to  adherens  junctions  and  its 
degradation is required for cell migration. Inhibition of HDAC6 causes a substantial increase in 
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β-catenin levels thus inhibiting migration; of given importance, HDAC6 activity is required for 
β-catenin nuclear translocation and its inhibition negatively affects not only cell migration but 
even cell proliferation [155-158] . 
4.5 MICROTUBULES AND CELL DIVISION
The  mitotic  spindle  is  a  bipolar,  self-organizing  microtubule  based  machine  that  accurately 
segregate sister chromatids into the daughter cells during division. The dynamic properties of 
microtubules  are  obviously important  for spindle morphogenesis  as  well  as force generation 
within the spindle. The first sign of microtubule dynamic alterations is in prophase when long 
interphase microtubules disappear and are replaced by shorter, less stable and more numerous 
mitotic microtubules that nucleate form the centrosome.
Fig  28.  Microtubules  dynamics  in  mitotic  cells.  A:  different  phases  of  mitosis  progression  with  related 
microtubules organization. B spindle poles microtubule subclasses at metaphase. Graphical rielaboration of  [108, 
159] 
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Position, organization and functionality define three distinct subclasses of microtubules in the 
mature mitotic spindle: the astral ones, the interpolar ones and the kinetochore ones (K-fibers).
Astral microtubules originate from the two centrosomes and extend all the way to the cell cortex. 
They have a major role in centrosome separation during prophase and in spindle positioning; 
they are involved as well in activating the assembly of actin and myosin ring that is fundamental  
for cytokinesis [108, 160].
The interpolar microtubules are the most dynamic and  abundant class and comprise the main 
body  of  the  mature  spindle.  They  don't  interact  with  chromosomes  but  emanate  from  the 
centrosome and extend towards the center of the spindle, where they interact in an antiparallel 
fashion  with  interpolar  microtubules  emanating  from  the  opposite  spindle  pole.  The  most 
important function of these fibers is  the establishment and maintenance of spindle bipolarity 
[108, 161].
K-fibers are bundles of 20–40 parallel MTs whose main function is to attach the chromosomes to 
the  two  spindle  poles  and  to  segregate  the  sister  chromatids  into  the  daughter  cells.  The 
mechanism driving the assembly of the K-fibers is still not fully understood. The attachment to 
the kinetochore occurs progressively as the cell  moves from prometaphase to anaphase,  in a 
process called K-fiber maturation. Erroneous K-fiber–kinetochore attachments are released for 
error  correction  through  a  mechanism  involving  the  targeting  and  regulation  of  various 
kinetochore factors by the kinase Aurora B. It has been shown that the loss of tubulin subunits at 
the K-fiber minus-end occurs without spindle pole detachment and drives the polewards tubulin 
flux. This mechanism is sufficient for generating pulling forces at the kinetochores that stretch 
the centromeres in metaphase. In anaphase, dramatic changes in K-fiber dynamics promote their 
shortening and chromosome segregation [161-163].
During  mitosis  microtubule  can  originate  through  three  different  pathways,  centrosomal, 
chromosomal  and  microtubule-dependent,  all  of  them cooperating  to  form the  spindle.  The 
centrosome asters define the position of the two spindle poles and the axis of cell division; the 
chromosomal microtubules facilitate the capture of the kinetochores and the formation of the K-
fibers; the microtubules amplification contributes to the strengthening of the whole structure. 
The combination of the three pathways could therefore allow the timely assembly of the bipolar 
spindle and allow mitosis to progress successfully [161].
Mitosis initiation and progression is regulated by a complex machinery, with different activities 
being switched on and off at precise times and locations throughout the cell. One essential player 
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is the chromosomal passenger complex (CPC), which comprises Aurora-B protein kinase, the 
inner centromere protein INCENP, survivin and borealin. CPC localization is highly dynamicis 
and regulates  at  the same time chromosomal arrangements and spindle pole organization by 
correcting nonbipolar microtubule-kinetochore interactions. In prophase, the CPC is found on 
chromosome arms  where  it  phosphorylates  histone  H3  on Ser10  and  Ser28,  an  early event 
required for chromosome condensation. During this phase it accumulates at centromeres where 
the maturation of kinetochores begins and continues through prometaphase. The CPC is required 
for the  formation of a bipolar spindle and its stability from prophase/prometaphase to anaphase. 
In metaphase, it localizes at centromeres, where it has a central role in centromeric cohesion and 
the  regulation  of  kinetochore–microtubule  attachments.  It  controls  the  correct  alignment  of 
chromosomes  on  the  spindle  equator  and  the  spindle  checkpoint.  In  anaphase,  the  CPC 
translocates to the spindle midzone and appears at the cortex; it is involved in the formation of 
the central spindle. In telophase, the CPC concentrates at the cleavage furrow and, subsequently, 
at the midbody, where it is required for completion of cytokinesis [164-165].
Fig 29.  Microtubules organization and CPC localization through mitosis. CPC is fundamental in organizing 
mitotic progression through different phases. CPC localization is represented in red and fundamental actions are 
described. Microtubule rearrangements are represented in green.
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4.6 MICROTUBULES AND CANCER THERAPY
Microtubules  play  an  important  part  in  an  array  of  cellular  functions  including  mitosis, 
movement of organelles, vesicles and proteins, development and maintenance of cell shape and 
growth.  The  complex  dynamics  of  microtubules  are  highly  regulated  and  sensitive  to 
manipulation. If bipolar spindle dynamics are compromised, mitotic block or slowing occurs at 
the  metaphase-anaphase  transition,  eventually  leading  to  apoptosis.  Agents  that  disrupt 
microtubule dynamics play key roles in both curative and palliative cytotoxic chemotherapeutic 
regimens [166-167].
Drugs  that  interferes  with  microtubular  structure  and  function  are  classically  divided  into 
stabilizers and destabilizersMicrotubule destabilizers consist predominantly of drugs that act at 
the Vinca alkaloid and colchicine-binding sites. The oldest class of cytotoxic agents that interfere 
with microtubules are the Vinca alkaloids; these agents are active in a variety of malignancies 
including lymphomas, non-small cell lung cancer (NSCLC), and breast cancer. It is thought that 
the  Vinca  alkaloids  interact  with  the  central  portion  of  the  b-tubulin  subunit  peventing 
polymerization. Colchicine acts at a separate site on b-tubulin named the colchicine-binding site 
[168]. 
Until recently, the only clinically important microtubule stabilizers were the taxanes, such as 
paclitaxel and docetaxel. Taxanes are widely used cytotoxic agents that are active in a range of 
solid  tumor  malignancies  such  as  breast  cancer,  NSCLC,  ovarian  cancer,  gastroesophageal 
cancer, germ cell tumors, as well as cancers of the head and neck. They are routinely used in the 
neoadjuvant, adjuvant, and metastatic setting alone and in combination with drugs with different 
mechanisms of action and nonoverlapping toxicity profiles. The taxanes bind to tubulin, stabilize 
the microtubule, and inhibit its disassembly leading ultimately to cell death by apoptosis  [168-
169].  The clinical  use of  the taxanes  is  limited by tumor resistance,  risk of  hypersensitivity 
reactions  and toxicity.  Acquired and intrinsic  resistance of  tumor  cells  to  taxanes  remains  a 
significant clinical problem.  It occurs through a variety of mechanisms, most important one 
being the expression of multidrug resistance proteins such as P-glycoprotein, which belongs to a 
family of ATP-binding cassette transporters and which is the product of the multidrug resistance-
1 gene. Resistance to the taxanes can also occur due to interruption of the interaction between the 
drug and the target protein, b-tubulin: tumor cells can overexpress the bIII isoform of tubulin 
leading  to  demonstrable  clinical  resistance;  intrinsic  and  acquired  mutations  in  the  tubulin 
protein can interfere with the normal binding of taxanes to the target protein; altered expression 
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of microtubule-associated proteins can also prevent taxane binding [167].
Epothilones are macrolide antibiotics that cause microtubular stabilization and cellular arrest in a 
similar way to the taxanes. They bind to the tubulin-binding pocket in a specific and independent 
manner,  suggesting  that  rather  than  a  common pharmacophore  for  taxanes  and epothilones, 
tubulin has a promiscuous binding pocket, allowing different molecules to interact according to 
their unique structures [170].
Laulimalide is a structurally complex substance derived from marine sponges that also maintains 
antimitotic  activity  against  paclitaxel-resistant  cells.  The  interaction  of  laulimalide  and 
microtubules is complex, but there is evidence for a distinct laulimalidebinding site on a-tubulin. 
Xenograft studies in mice have shown that the drug has a narrow therapeutic index and marked 
toxicity without evidence of efficacy, probably limiting its further development [171-172].
Fig 30. microtubules stabilizers and destabilizers. Adapted from [167].
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CHEMICALS
SP600125 (1,9-Pyrazoloanthrone), MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide ), Monoclonal anti-β-Catenin antibody 6F9, Monoclonal Anti-α-Tubulin, 
clone DM1A, Monoclonal Anti-Acetylated Tubulin Clone 6-11B-1, L-Glutamine Solution 200 
mM, Sodium Pyruvate Solution 100mM, Dulbecco's PBS, PBS tablets,  Trypsin EDTA Solution, 
Penicillin/Streptomicyn Solution, Foetal Bovine serum, were purchased from Sigma-Aldrich.
p53 antibody, caspase3 antibody, Phospho-p53 (Ser46) Antibody, p53 (1C12) Mouse mAb, p27 
Kip1 (D69C12)XP Rabbit mAb, p21 Waf1/Cip1 (DCS60) Mouse mAb, p21 Waf1/Cip1 (12D1) 
Rabbit mAb, Acetyl-p53 (Lys382) Antbody, Phospho-p53 (Ser15) Antibody, HDAC (D2E5) 
Rabbit mAb, PARP Antibody were purchased from Cell Signaling Technologies.
Purified Mouse Anti-Actin Ab-5  was purchased from BD Biosciences.
Goat anti Rabbit IgG, (H+L) HRP conjugate, Goat anti-Mouse IgG Antibody, Peroxidase 
Conjugated, H+L Ischemin (MS120), pifithrin-μ (CAS 64984-31-2) were purchased from Merk 
Millipore.
Wheat Germ Agglutinin 594 conjugate,  LysoTracker Red DND-99, ProLong Gold Antifade 
Reagent with DAPI, Alexa Fluor 488 F(ab')2 Fragment of Goat Anti-Rabbit IgG (H+L) 
Antibody, Alexa Fluor 488 F(ab')2 Fragment of Goat Anti-Rabbit IgG (H+L) Antibody, Alexa 
Fluor® 555 F(ab')2 Fragment of Goat Anti-Rabbit IgG (H+L), Goat serum New Zealand, 
DMEM GlutaMAX™ Supplement , DMEM/F-12 GlutaMAX™ Supplement, Ham's F-12 
Nutrient Mix, GlutaMAX™ Supplement, Ham's F-12K (Kaighn's) Medium were purchased from 
Life Technologies.
RPMI 1640 medium was purchased from EuroClone.
cOmplete, Mini Protease Inhibitor Cocktail Tablets were purchased from Roche.
NE-PER Nuclear and Cytoplasmic Extraction Reagents, TUBB1 antibody, Phospho-Histone H3 
pSer10 Antibody, Restore Western Blot Stripping reagent were purchased from Thermo 
Scientific.
HDAC Activity/Inhibition Direct Assay Kit (Colorimetric) was purchased from Epigentek.
MycoAlert Mycoplasma Detection Kit was purchased from Lonza.
Caspase-Glo 3/7 Assaywas purchased from Promega.
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Proteome Profiler Human Phospho-Kinase Array was purchased from R&D Systems.
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CELL CULTURE  
All thyroid cancer cell lines were stored in liquid nitrogen. For defrosting, cells were placed in 
37°C water bath, gently shaken for 1 minute and then immediately seeded in pre-warmed culture 
media. The day after, media was changed and cells cultured for at least 10 days before 
experiments being performed. 
All cells were grown as monolayers in 100 mm plastic culture dishes and kept in a humidified 
incubator at 37°C under 5 % CO2, with media change every 3-4 days. Cells were passaged when 
reaching 70-80 % confluency.
All cell lines had been identified of thyroid cancer derivation [173].
All cell lines were routinely screened for mycoplasma contamination with MycoAlert 
Mycoplasma Detection Kit (Lonza).
D
T
C
FTC-133 Description FTC-133 was obtained from a FTC lymph node metastasis of a 42-year-
old male. Grown as monolayer. The morphology differs from flat 
polygonal to spindle formed cells. They retained differentiated thyrocyte 
function and thyrocyte responsiveness to thyrotropin and local active 
growth factors. [174-176]  
Colture Media DMEM : Ham's F12 supplemented with 10% FBS, 2mM L-Glutamine; 
Genetics PTEN -/R130*, p53 R273H 
TPC-1 Description Obtained from a papillary thyroid carcinoma of a female patients. 
Retains thyroid differentiation markers. Grown as monolayer organized 
in multi-cellular, trabecula-like structures. [177-182]     
Colture Media RPMI supplemented with 10% FBS, 1 mM sodium pyruvate, 2mM L-
Glutamine.
Genetics RET/PTC1,  t (1;10;21)
PD
T
C
HTC/C3 Description Human thyroid carcinoma established from cancer cells disseminated in 
the pleural fluid of a 44-year-old japanese woman with undifferentiated 
giant cell carcinoma of the thyroid. Epithelial-like cells growing as 
monolayer. [183]
Colture Media DMEM supplemented with 10% FBS, 2mM L-Glutamine.
Genetics BRAF V600E/WT, p53 P152L, DUSP26 amplification 
SW579 Description Squamous cell thyroid carcinoma established from 59 years old 
caucasian male in 1973. Epithelial cells growing as monolayer. [176, 
184-186]  
Colture Media Ham's F12 supplemented with 10% FBS, 2mM L-Glutamine.
Genetics P53 I255S 
50
MATHERIALS & METHODS
AT
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SW1736 Description Anaplastic thyroid carcinoma originally developed by Leibowitz and 
McCombs III at the Scott and White Memorial Hospital (Temple, TX) in 
1977. Their epithelial origin was confirmed by demonstration of 
cytokeratin expression. Grown as monolayer. [187-189] 
Colture Media DMEM  supplemented with 10% FBS, 2mM L-Glutamine.
Genetics BRAF V600E/WT, p53 -/- 
Hth74 Description Human anaplastic thyroid carcinoma cell line was isolated from thyroid 
carcinoma tissue of a 73-year-old woman. HTh74 cells were shown to 
express some thyroid specific genes like functional TSH receptor protein, 
and mRNA for thyroglobulin, albeit both at very low levels.Epithelial-
like, grown as monolayer. [176, 189-190]  
Colture Media DMEM supplemented with 10% FBS, 2mM L-Glutamine.
Genetics P53 K286E, Akt pathway hyperactivation
M
T
C
TT Description The TT cell line was established from a 77 year old female with thyroid 
medullary carcinoma. 
Epithelial-like, grown as monolayer; TT cells continuously produce high 
levels of calcitonin and CEA. Chromosomal analysis of the cell line 
reveal an aneuploid human karyotype with several marker chromosomes. 
Harbour a MEN2A-type mutation. [191-193]  
Colture Media Ham's F12K supplememted with 10% FBS 
Genetics RET C634W
Table 6. Cell lines used in this study and their main characteristics.
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MTT PROLIFERATION ASSAY
Cells were seeded at the optimal density in 96-well plates with the exception of the outer wells;
after 24 hours cells were treated with SP600125 diluited in the appropriate colture media 
(100μL/well) at concentrations in the range 0-50 μM and incubated for the given time (0-96h).
On the day of the assay MTT (Sigma) solution (5 mg/ml in PBS) was equilibrated at room 
temperature and 10μL were added to each well to a final concentration of  0.5 mg/ml; from this 
moment exposure to direct light was avoided.
The plates were incubated at 37˚C and 5 % CO2  for 2 hours for all cells except TT which 
required 4 hours, colture media was then gently removed and formazan crystals solubilized in 
200μL of EtOH:DMSO 1:1 solution. After 5 minutes solubilization on a plate shaker assorbance 
was red at 540nm using ELx800 Absorbance Microplate Reader (BioTek).
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CELLULAR FRACTIONING
The cellular fractioning was performed with NE-PER Nuclear and Cytopalsmic Extraction 
Reagents (Thermo Scientific) kit.
Cells were seeded at the optimal density in 6 cm petri dishes and after 24 hours treated with 
DMSO or SP600125 10 μM. Cells were harvested with trypsin-EDTA, pelleted and resuspended 
in PBS. 2.000.000 cells were tranferred to a new tube, pelleted and PBS was completely 
removed. Samples were resuspended in 200 μl of ice cold CER I buffer, vortexed on the highest 
setting for 30 seconds and incubated on ice for 10 minutes. CER II buffer was added, followed 
by 10 minutes vortexing twice, separated by 1 minute incubation on ice. Samples were 
centrifuge at 14500g for 5 minutes and the surnatant containing cytoplasmic extract immediately 
transferred to a new tube. Pellets were suspended in ice cold NER buffer and vortexed for 15 
seconds every 10 minutes for a total of 40 minutes, followed by centrifugation at 14500g for 10 
minutes. Surnatant containing the nuclear fraction was transferred to a new tube and the pellet 
discharged.
Cytoplasmic and nuclear extracts were sonicated and analyzed by electrophoresis and western 
blotting on 4-12% acrilammide gels. For assess of correct cellular fraction separation GAPDH 
was used as cytoplasmic marker while PARP was used as nuclear marker.
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CO-IMMUNOPRECIPITATION ASSAY
Co-immunoprecipitation (Co-IP) is a popular technique to identify physiologically relevant 
protein-protein interactions by using target protein-specific antibodies to indirectly capture 
proteins that are bound to a specific target protein. 
Cells were seeded at the optimal density in 10 cm petri dishes and after 24 hours treated with 
DMSO or 10 μM SP600125.
Cells were washed twice with warm PBS and then lysed with 500μl of hypotonic buffer (150 
mM NaCl, 1 mM EDTA, 0.5% NP40, 20 mM Tris-HCl (pH 7.5) plus freshly added protease 
inhibitors cocktail); cells were collected in tubes and incubated for 15 min on ice in agitation. 
Samples were then centrifuged 14000g for 10 minutes and surnatant immediately transferred to 
new tubes. 
Protein G-sepharose (Protein G Sepharose 4 Fast Flow, GE Healthcare) was washed twice with 
PBS and 100 μl of Protein G-sepharose:PBS 1:1 solution was added to each sample followed by 
1h incubation at 4°C in agitation. After centrifugation at 14000g for 10 minutes surnatant was 
transferred to new tubes and total protein amount quantified with DC Protein Assay (BIORAD); 
all samples were diluited in PBS to obtain final protein concentration of 1 μg/ml (total extract 
fraction).
2 μl of primary antibody against acetyl-α-tubulin was added to 500 μl of each sample followed 
by over night incubation at 4°C in agitation.
On the following day 100 μl of Protein G-sepharose:PBS 1:1 solution was added to each sample 
followed by 2h incubation at 4°C in agitation. After centrifugation at 14000g for 10 minutes the 
surnatant was transferred to new tubes (surnatant fraction); the pellet containing 
immunoprecipitated proteins was washed twice with PBS, resuspended in 50 μl of lysis buffer 
and boiled for 5 minutes (immunoprecipitated fraction); after centrifugation at 14000g for 10 
minutes the surnatant was transferred to new tubes and the whole sample was analyzed by 
electrophoresis and western blotting.
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TUBULIN POLYMERYZATION ASSAY
An in situ cellular assay was used, in which the tubulin monomer (soluble) and polymer 
(unsoluble) forms were separated by centrifugation in hypotonic buffer and relative amounts 
analyzed by electrophoresis and Western blotting [194-195].
Cells were seeded at the optimal density in 6 cm petri dishes and after 24 hours treated with 
DMSO or 10 μM SP600125.
All buffers were mainteined at 37°C to avoid temperature-dependent variations in tubulin 
polymerization.
Cells were washed twice with warm PBS and then lysed with 100μl of hypotonic buffer (1 mM 
MgCl2, 2 mM EGTA, 0.5% NP40, 20 mM Tris-HCl (pH 6.8) plus freshly added 2 mM PMSF 
and protease inhibitor cocktail) for 10 minutes at 37˚C. Cells were collected in tubes and the 
particulate fraction was separated from the soluble cytosolic fraction by centrifugation at 14000g 
for 10 minutes. Surnatant containing the monomeric tubulin was immediately collected and 
transferred to a new tube while the pellet containing the polymeric form was resuspended in 
equal amount of hypotonic buffer. 
All samples were sonicated and analyzed by electrophoresis and western blotting on 10% 
acrilammide gels.
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PROTEIN EXTRACTION AND WESTERN BLOTTING
Samples preparation
Cells were seeded at the optimal density in 6 cm petri dishes and after 24 hours treated with 
DMSO or 10 μM SP600125.
For phospho-protein evaluation cells were washed with PBS and then lysed with 100 μl of 
Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 5% SDS) supplemented with freshly added protease 
inhibitors (cOmplete Mini, Roche) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail 2, 
Sigma) pre-warmed in boiling water [196]. Samples were collected in pre-chilled tubes, boiled 
for 3 minutes and sonicated.
For all the other samples, cells were washed with PBS and lysed with ice-cold RIPA buffer (50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% SDS, 1% NP40, 1% Sodium deoxycholate, 2 mM 
EDTA) supplemented with freshly added protease inhibitors (cOmplete Mini, Roche) and 
phosphatase inhibitors (Phosphatase Inhibitor Cocktail 2, Sigma), collected in pre-chilled tubes 
and sonicated [197-198]. For apoptosis evaluation cell medium was collected to new tubes, cells 
harvested with trypsyn and added to their own medium. After pelleting cells were resuspended in 
supplemented RIPA buffer, collected in pre-chilled tubes and sonicated.
Protein amount was quantified with bicinchoninic acid method (BCA Protein Assay Reagent, 
thermo Scientific) [199] and for each sample the same protein amount was prepared with 10X 
Denaturing Sample Buffer (500mM Tris-HCl pH 6.8, 10% SDS, 60% Glycerol, 10% β-
mercaptoethanol, 0.04% bromophenole blue), boiled for 5 minutes and analyzed by 
electrophoresis.
Electrophoresis
All samples with the exception of tubulin polymerization assay and Co-Immunoprecipitation 
ones were resolved with Novex NuPAGE® SDS-PAGE Gel System on NuPAGE® Novex 4-
12% Bis-Tris Gels in MOPS Running Buffer. Tubulin Assay and Co-Immunoprecipitation 
samples were resolved on 10% acrylamide gels in Running Buffer (250 mM Tris, 1.92 M 
Glycine, 10% SDS).
Protein transfer was performed with iBlot Blotting System (Life Technologies) on iBlot Transfer 
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Stack, Nitrocellulose, followed by Ponceau Staining as control.
Immunoblotting
Nitrocellulose membranes were incubated for 1 hour in 5% milk in TBS-T (30 mM Tris-HCl pH 
7.5, 150 mM NaCl, 0.1% Tween-20) in agitation, washed three times with TBS-T and incubated 
over night at 4°C with primary antibody following manufactor instruction. The following day 
membranes were washed three times with TBS-T and incubated for 1 hour in secondary antibody 
solution (anti rabbbit or anti-mouse HRP-conjugated Ab (Millipore), 1:5000 in 5% milk in TBS-
T). 
Detection
After three times washing with TBS-T, a chemiluminescence-based immunodetection was 
performed with Novex ECL Chemiluminescent Substrate Reagent Kit; Amersham Hyperfilm 
ECL (GE Healthcare) were exposed for different times in a dark room and manually developed 
(Kodak Dental Readymatic Developer and Fixer). Images were quantified with ImageJ software.
Antibody productor code Concentration Solution (TBS-T)
actin BD 612657 1:5000 5% milk
Acetyl-p53 Lys382 Cell Signaling #2525 1:1000 5% BSA
Acetyl-tubulin Lys40 Sigma T6793 1:1000 2.5% milk
β-catenin Sigma C7207 1:1000 5% BSA
Caspase3 Cell Signaling #9662 1:800 2.5% milk
GAPDH Santa Cruz sc-25778 1:2000 5% milk
HDAC6 Cell Signaling #7558 1:1000 5% BSA
p21 Cell Signaling #2947 1:1000 5% BSA
p27 Cell Signaling #3686 1:1000 5% BSA
p38 Cell Signaling #9212 1:1000 5% BSA
p53 Cell Signaling #9282 1:1000 5% milk
PARP Cell Signaling #9542 1:1000 5% milk
Phospho-Histone H3 Ser10 Thermo Scientific PA5-17869 1:1000 5% BSA
Phospho-p38 Thr180/Tyr182 Cell Signaling #9212 1:1000 5% milk
Phospho-p53 Ser15 Cell Signaling #9284 1:1000 5% BSA
Phospho-p53 ser46 Cell Signaling #2521 1:1000 5% BSA
tubulin Sigma T9026 1:2000 2.5% milk
Table 7. Antibodies and settings used in western blot assays.
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IMMUNOFLUORESCENCE AND CONFOCAL IMAGING
Cells were seeded at the optimal density on 22x22 mm glass slides and after 24 hours treated 
with DMSO, 10 μM and 20 μM SP600125. 
For cell membrane visualization living cells were incubated with 5 μg/ml Wheat Germ 
Agglutinin Alexa-Fluor 594 Conjugate (Life Technologies) in PBS for 10 minute at 37°C in 5% 
CO2 prior to samples fixation.
For lysosome visualization living cells were incubated with 1μM LysoTracker® Red DND-99 
(Life Technologies) in appropriate colture medium for 2 hours at 37°C in 5% CO2 prior to 
samples fixation.
Samples were washed three times with pre-warmed PBS and fixated by incubation for 10 
minutes in pre-warmed 4% PFA in PBS except for membrane and lysosme visualization where it 
was used a 2% PFA solution. After washing with PBS cells were pearmibilized with 0.2% Triton-
X in PBS for 10 minutes and then incubated for 1 hour RT with 5% goat serum in PBS. After 
washing, cells were incubated over night at 4°C with primary antibody solution. On the 
following day cells were washed three times in PBS, secondary antibody solution (anti-rabbit 
Alexa-Fluor 564 conjugate or anti-mouse Alexa-Fluor 488 conjugate, Life Technologies, 1:500) 
was added, and 1 hour incubation was performed in the dark. After PBS washing samples were 
mounted on microscope slides with 15 μl of ProLong Gold Antifade Reagent with DAPI (Life 
technologies) 
Images were acquired with Nikon EclipseTi-E inverted microscope with IMA10X Argon-ion 
laser System by Melles Griot; all images were acquired with CFI Plan Apo VC 60X Oil (Nikon) 
objective except those for mitotic index  that were acquired with CFI Plan Apo VC 20X (Nikon) 
objective. p53, Acetyl-tubulin and WGA stained cells were acquired with ulterior 1.3x digital 
zoom. Mitotic morphology cells were acquired with ulterior 5x digital zoom. Migrating cells 
details were acquired with ulterior 4x digital zoom. For microtubules, mitosis and migration 
imaging whole cells were acquired with Z-series acquisition, 0.15 μm step and 3D structure 
reconstucted with NIS-Elements AR software.
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Antibodies & Dyes productor code Concentration Solution (PBS)
Acetyl-tubulin Sigma T6793 1:500 5% goat serum
β-catenin Sigma C7207 1:200 5% goat serum
Lysotracker Life Technologies L-7528 1μM DMEM or RPMI
p53 1C12 Cell Signaling #2524 1:200 5% goat serum
Phospho-Histone H3 Ser10 Thermo Scientific PA5-17869 1:250 5% goat serum
Phospho-p53 Ser15 Cell Signaling #9284 1:250 5% goat serum
tubulin Sigma T9026 1:500 5% goat serum
Wheat Germ Agglutinin Life Technologies W11262 5.0 µg/mL PBS
Table 8. Antibodies and settings used in immunofluorescence experiments.
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CASPASE ACTIVITY ASSAY
Caspase activity was measured with Caspase-Glo 3/7 Assay (Promega). Cells were seeded at the 
optimal density in 96-well white and transparent plates with the exception of the outer wells; 
after 24 hours they were treated with DMSO or 10 μM SP600125 for 0-72h.
On the day of the assay reagents were bring to room temperature and to each well of the white 
plastic plate 100μl of reconstituted Caspase-Glo Reagent was added.  After 30 seconds shake, 
plates were incubated in the dark at room temperature for 1 hours. Fluorescence was measured 
using a Fluoroskan Ascent FL Microplate Reader (Thermo Scientific) luminometer.
At the same time MTT assay was performed on the transparent plates to determine cell viability 
and variations in cell number.
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PHOSPHO-KINASE ANTIBODY ARRAY
The assay was performed using manufacture instructions.
Cells were seeded at the optimal density in 10 cm petri dishes and after 24 hours treated with 
DMSO or 10 μM SP600125; after 60h samples were extracted in 400μl of Lysis Buffer 6.
After 30 minutes incubationon ice on a rocking platform samples were centrifuged at 14000g for 
5 minutes, the surnatant transferred to new tube and total protein amount quantified.
A and B membranes were blocked in 1ml of Array Buffer 1 for 1 hour at room temperature. 
Blocking buffer was discharged and 300 μg of proteins eluted in array buffer 1 to a total amount 
of 2 ml were added to each membrane. Membranes were then incubated at 4°C overnight on a 
orbital shaker.
The following day membranes were washed in 20 ml of washing buffer and each one was 
incubated in 1 ml of reconstituted detection cocktail for 2 hours at room temperature on a orbital 
shaker. After washing each membrane was incubated with 1 ml of streptavidin-HRP conjugated 
for 30 minutes room temperature, washed and developed with 500 μl of ChemiReagent mix.
Analysis was performed with ImageJ software.
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WOUND HEALING ASSAY
Cells were seeded at the optimal density in 6-well multiwell and after 24 hours treated with 
DMSO or 10 μM SP600125; after 72h cells were scraped with a p200 tip, washed with PBS and 
returned to control or treated medium. Images were acquired at 0, 12 and 16h with Kodak 
EasyShare C195 camera on Olympus CK2 microscope with A10PL 10X objective.
Wound dimensions were quantified with ImageJ software.
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HDACs ASSAY
The assay was performed with Epigenase HDAC Activity/Inhibition Direct Assay Kit 
(colorimetric) with minimal modifications to manufacter's instruction. 
Cells were seeded at the optimal density in 10 cm petri dishes and after 24 hours treated with 
DMSO or 10 μM SP600125. On the day of the assay cell fractioning was performed with  NE-
PER Nuclear and Cytopalsmic Extraction Reagents as described, using doubled number of cells 
to obtain high concentrated samples. HDAC activity was tested in both nuclear and cytoplasmic 
fractions, control samples with 5 μM TSA were used as inhibition control. Samples (15μg for 
cytosol and 10μg for nuclear extracts) and standard curve (range 0.1-4ng/μl) were added to plate 
wells, sealed with adhesive film and incubated for two hours at 37°C in the dark. After washing 
50 μl of HO4 solution were added to each well and then incubated for 1 hour room temperature 
in the dark. After washing 50 μl of HO5 solution was added and incubated for 30 minutes at 
room temperature in the dark. After washing 100 μl of Developing Solution were added and 
incubated at room temperature for 20 minutes in the dark; a blue color developed in presence of 
HDACs activity. 100 μl of Stop Solution were added and absorbance readed at 450 nm with 
reference background at 655nm. 
On the same samples a western blot was performed to assess the amount of HDAC6 in the 
different samples.
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PATHWAYS ANALYSIS
STRING (Search Tool for the Retrieval of  Interacting Genes/Proteins)
STRING [49, 200]  is an on-line database, a meta resource that aggregates most of the available 
information on protein-protein associations, scores and wheights it, and augmants it with 
predicted interactions as well as with the results of automatic literature-mining searches.
The basic interaction unit in STRING is the “functional association” , which is defined as the 
specific and meaningful interaction between two protein that jointly contribute to the same 
functional process. 
The STRING website aims to provide easy and intuitive interfaces for searching and browsing 
the protein interaction data, as well as for inspecting the underlying evidence. Users can query 
for a single protein of interest,or for a set of proteins, using a variety of different identifier name 
spaces. 
The resulting network can then be inspected, rearranged interactively or clustered at variable 
stringency. Each protein node in the network shows a preview to 3D structural information, if 
available, and can be clicked to reveal a pop-up window with more information about the protein 
(including its annotation, SMART domain-structure, structure homology models from SWISS-
MODEL Repository  etc).
Each edge in the network denotes a known or predicted interaction, and leads to a pop-up 
window providing details on the underlying evidence and the interaction confidence scores.
Fig 31: STRING user's interface. A: protein selection tool; B: resulting network.
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An interactive view allows for rearrangement and ad-hoc clustering of nodes; three modes 
provides different views on the network: 
• confidence view: single edges connect the items with thickness proportional to the 
confidence;
• actions view: each edge represents a given type of action, like activation, inhibiton or 
binding;
• evidence view: each edge represents a given type of evidence, like text mining or 
experimental evidence.
STITCH (Search Tool for Interacting Chemicals) 
STITCH [201-203] is a interactive database about chemicals-proteins interaction knowledge. It 
enables the user to search by compound name displaying a network view of most probable 
interactions; for proteins and chemicals the structure annotations and links to source databases 
are shown while for edges available scores are shown. More than 300000 chemicals interactions 
are available, with more than 110000 high-confidence interactions and more than 250000 high-
confidence edges for interactions between chemicals and human proteins. To provide crucial 
context for the aggregated protein-chemicals interactions, protein-protein interactions from 
STRING database are incorporated into a seamless network view.
An interactive view allows for rearrangement and ad-hoc clustering of nodes; three modes 
provides different views on the network: 
• confidence view: single edges connect the items with thickness proportional to the 
confidence;
• actions view: each edge represents a given type of action, like activation, inhibiton or 
binding;
•  evidence view: each edge represents a given type of evidence, like text mining or 
experimental evidence.
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Analysis parameters
SP600125 interactions have been indagated with STITCH 3 while protein-protein interactions 
have been indagated with STRING v9.1.
For both analysis the following settings were used:
• co-occourrence, co-expression, experiments and databases were selected as active 
predicting methods;
• confidence score was setted as > 0.700 (high);
• node enrichment +10 nodes
• custom limit of no more than 20 interactors shown;
• network clustering with MCL algorithm;
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DATA ELABORATION AND STATISTICAL ANALYSIS
All western blot and cell migration quantifications were made with ImageJ Software, version 
1.47
All confocal microscopy based quantifications were made with Nikon NIS-Elements Software, 
followed by ImageJ analysis when required.
All statistical analysis were performed with GraphPad Prism Software, version 5.04 on a 
minimum of four replicates. Values are expressed as mean standard error. One-way or two-way 
ANOVA followed by appropriated post-hoc test were used to evaluate differences between 
means.
On the whole document significativity levels were reported as follows:
* p<0,05 
** p<0,01
*** p<0,001 
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1 EFFECTS ON CELL PROLIFERATION
1.1 SP600125 AFFECTS CELL PROLIFERATION.
Since it has recently been demonstrated that SP600125 is able to inhibit the proliferation of p53 
null cells [57], for first it was tested on six thyroid cancer derived cell lines with different p53 
status: three cell lines harboring p53 point mutations (HTC/C3, Hth74 and SW579), one with a 
pseudo-null status (SW1736) and two p53 wild type ones (TPC1 and TT). Cells were exposed to 
different concentrations (0-50 μM) for different periods of time (0-96h) and viability asessed 
with MTT assay. 
Fig 1. Effects on cell proliferation. Cells were incubated for 96h with the indicated concentrations of SP600125 
and then viability was assessed with MTT assay; DMSO was used as control. A: dose dependent growth inhibition 
(% control); B: differences in cells growth inhibition correlated with p53 status. MUT p53 metated cells, NULL p53 
null cells, WT p53 wild type cells.
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The results shown that SP600125 was able to reduce cell growth with various efficacy in a time 
and concentration dependent way (Fig 1A). Moreover, if proliferation data are grouped by p53 
status, it can be noticed that there are significant differences in growth inhibition (Fig 1B) and 
that these differences are exacerbated with an increase in dose and time of incubation: while at 
10 μM only p53 mutated cell lines exhibited significant growth inhibition compared to wild type, 
at 20 μM significant effects were obtained also on p53 null cells. From the obtained data it can 
be inferred that SP600125 acts preferentially on cell lines with altered p53, with much more 
efficacy on point mutations vs. null status. On the basis of obtained results, the concentrations of 
10  μM and 20 μM were chosen for further experiments. 
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2 EFFECTS ON P53
2.1 SP600125 INFLUENCES P53 LOCALIZATION
As long as SP600125 action was confirmed be influenced by p53 status, to clarify p53 
involvement further experiments were performed. Fist of all, as p53 nuclear translocation plays 
an important role inits activation, subcellular localization was analyzed by confocal microscopy 
analysis and cellular fractioning experiments.
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◄Fig 2. Effects on p53 subcellular localization. Cells were incubated with SP600125 or DMSO for 72h and then 
immunofluorescence (A,C) or cellular fractioning and western blotting (B,D) were performed. PARP and GAPDH 
were used as nuclear and cytosolic markers, respectively.  A, B: SP600125 treatment induced p53 nuclear 
translocation in HTC/C3 cells; C,D: SP600125 had no effects on the wild type p53 in TPC1 cells.
Interestingly SP600125 caused a significant variation of p53 localization in HTC/C3 cells: after 
72h of exposure an intense nuclear staining was detected in HTC/C3 cell line (Fig 2 A) and this 
data was confirmed by cellular fractioning showing a marked increase in the nuclear fraction of 
p53 (Fig 2 A). Conversely no variations were detected in p53 WT TPC1 cells (Fig 2 C,D) and no 
signal was detected in p53 pseudo-null SW1736 (data not shown).
Moreover, as p53 is transported to the nucleus through microtubules, a co-immunoprecipitation 
assay was performed. After tubulin precipitation the different fractions were hibridized with anti-
p53 antibody. As it can be seen p53-tubulin binding reached a peak around 48 hours and as 
counterpart its levels diminished in the surnatant  fraction while no changes were detected on 
total protein extracts (Fig 3). This data are in complete agreement with the ones previously 
shown as p53 binds and it's transported on tubulin in the first 48h of treatment while its levels 
decreases in both the immunoprecipitated and the surnatant because by that time the majority is 
localized in the nucleus.
Fig 3. p53 bound tubulin at early time points. Cells were incubated with DMSO or SP600125 for the indicated 
times and then immunopreciptation was performed. The total protein extract, the immunoprecipitated and the 
surnatant fraction were resolved on polyacrilammide gels and p53 hybridization was performed. Shown are 
representative images and quantification of p53-tubulin bound fraction.
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2.2 SP600125 CAUSES P53 PHOSPHORYLATION AND P21 INDUCTION
As p53 nuclear translocation is one of the earliest step in the process of its activation, other 
modification involved in this process were investigated. 
Fig 4. SP600125 effects on p53 pathway. Cells were incubated with SP600125 or DMSO for 72h and then protein 
were estracted.  A: representative western blot images of mutated, null and WT p53 celll ines; B: relative western 
blot quantification.
It can be seen that an increase of p53 phosphorylation on serine 15 was detected in the p53 
mutated cell line (Fig 4), a post-translational modification known to mask a nuclear export signal 
and therefore enhancing p53 retaining within the nucleus, increasing interactions with 
CPB/p300, inducing other post-translational modifications that stabilize the protein and 
increasing its half-life and transactivational power. No other p53 phosphorylated residues were 
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detected (data not shown).
Concomitant to this modification an increase in p21 levels, a well-known effect of p53 activation 
was detected (Fig 4).
Moreover, as p53 activation is involved in apoptosis, the activation of this pathway was 
investigated through evaluation of caspase 3 cleavage and activity but the results showed only 
slight variations after 48h of incubation (data not shown), thus indicating that the apoptotic 
process is not involved in SP600125 mechanism of action.
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2.3 P53 IS PARTIALLY RESPONSIBLE OF SP600125 ANTIPROLIFERATIVE EFFECTS.
As long as it has been known that the three p53 mutations affecting our cell lines are supposed to 
impair p53 activity, further experiments were performed to elucidate if p53 phosphorylation and 
p21 induction were related and involved in SP600125 mechanism of action. The two main p53-
activities, transactivation and apoptosis induction were investigated with the use of two different 
p53 inhibitors: ischemin and pithfirin-μ, the first being an inhibitor of p53 transactivational 
activity and the latter an inhibitor of p53 pro-apoptotic activity through mitochondrial pathway. 
Fig 5. p53 transactivational activity inhibition partially revert SP600125 effects. Cells were incubated for 72h 
with DMSO, SP600125, pifithrin-μ and ischemin at the indicated concentration. A: pre-incubation with pifithrin-μ 
didn't affected SP600125 growth inhibition but show a slight synergysm; B: pre-incubation with ischemin partially 
reverted SP600125 growth inhibition in HTC/C3 cells; C: pre-incubation with ischemin partially reverted p21 
induction in HTC/C3 cells but had no effects on SW1736 and TPC1. CTRL control, SP10 SP600125 10μM, PFT5 
pifithrin-μ 5μM,  PFT10 pifithrin-μ 10μM,  ISCH5 ischemin 5μM,  ISCH10  ischemin 10μM.
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After pre-incubation with each of the p53 inhibitors, effects on cell proliferation and p21 levels 
were analyzed.First of all, as no results indication pro-apoptotic activity were detected, pre-
incubation with pithfirin-μ had no effects but a slight synergism on SP600125 growth inhibition 
(Fig 5A). Differently, pre-incubation with ischemin was able to significantly, although partially, 
revert SP600125 antiproliferative effects in HTC/C3 cell line, while it had no effects on SW1736 
and TPC1 cells (Fig 5B). Accordingly to these results, pre-incubation with ischemin induced a 
significant decrease in p21 induction only in HTC/C3 cells (Fig 5C), thus demonstrating a direct 
involvement of p53 and p21 in SP600125 antiproliferative effects.
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3 EFFECTS ON CELL MORPHOLOGY
3.1 SP600125 INDUCES ALTERATIONS IN CELLULAR AND NUCLEAR MORPHOLOGY
Previous results indicated that SP600125 causes alterations in p53 and p21, a pathway that 
usually regulates cell replication and senescence. For this reason further analysis were performed 
in this direction.
Fig 6. Effects on cellular morphology. Cells were incubated with SP600125 or DMSO for 72h and then images 
were acquired at light microscope or confocal after WGA and DAPI staining.  A: SP600125 treatment induced 
variations in cellular morphology and content; B: SP600125 treatment induces nuclear and cellular dimension 
alterations.
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First of all cell dimensions and morphology were characterized; the microscopical anlysis 
revealed that in affected cells there is a significant alteration in cellular morphology. At light 
microscope HTC/C3 cells appeared flattened, bigger, with increased amount of cytoplasmic 
vacuoles and more disomogeneous cytoplasmic content (Fig 6A). These alterations were 
accompanied by changes in nuclear morphology:  in treated cells different abnormalities were 
present, including giant, polylobated or multiple nuclei as well as micronuclei and cytoplasmic 
budding of chromatin fragments, increased nucleoli size and number, chromatin alterations with 
presence of disomogenities and heterochromatin condensation foci (Fig 6B). Only slight 
variations were detected in SW1736 cells and no alterations were found in TPC1 cells.
Following confocal analysis, cellular and nuclear dimensions were quantified, proving a 
significative increase in HTC/C3 cells and, to a lesser extent, in SW1736 (Fig 7).
Fig 7. Effects on cellular and nuclear dimensions.  Cells were incubated with SP600125 or DMSO for 72h and 
then immunofluorescence was performed. Tubulin and WGA staining were used for cellular area quantification 
while DAPI was used for nuclear staining and quantification.
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3.2 SP600125 INDUCES ALTERATIONS IN  LYSOSOME MORPHOLOGY AND 
LOCALIZATION
Confocal microscopy demonstrated an alteration in dimensions and subcellular localization of 
lysosomes. In HTC/C3 treated cells lysosomes appeared to be widespread in the cytosol, bigger 
and with more complex shape (Fig 8).
Fig 8. Variations in lysosome morphology.  Cells were incubated with SP600125 or DMSO for 96h and then 
lysosomes and nucleus were stained.
All these morphological alterations of cells, nuclei and lysosomes are higly specific of cellular 
senescence and in agreement with p21 levels increase following SP600125 treatment.
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4 EFFECTS ON MITOSIS PROGRESSION
4.1 SP600125 REDUCES THE MITOTIC INDEX OF P53 MUTATED CELLS
Given the previous results demonstrating an involvement of p21 and presence of nuclear 
alterations, the effects on mitosis were investigated. First of all the percentage of mitotic cells 
was quantified through staining with an antibody directed against Histone H3 phosphorylation at 
serine 10. The results showed that in HTC/C3 cell lines there is a significant decrease in 
phospho-histone H3 levels as well as in cells undergoing mitosis while in TPC1 only slight 
variations were detected; SW1736 showed an intemerdiated effect. Another difference existed 
between HTC/C3 and SW1736 cells: when looking at mitotic and pre-mitotic fractions it can be 
noticed that in HTC/C3 the bigger reduction is in the mitotic one while in SW1736 the ratio is 
conserved (Fig 9).  
Fig 9. Mitotic index. Cells were exposed to SP600125 or DMSO for 96h and then cells stained with Phospho 
Histone H3 and tubulin. Mitotic Index was quantified as percentage of pre-mitotic or mitotic cells on total cells 
number per optic fields at 20x objective.
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4.2 SP600125 INDUCES ABERRANT MITOSIS IN P53 MUTATED CELLS 
As second step mitosis morphology was investigated by confocal microscopy.
The results showed that in HTC/C3 there was an increase in the percentage of abnormal mitotic 
figures with  an increase in chromosome number, multiple spindle formation, impairment of 
chromosome alignment and segregation (Fig 10B). 
Systematic analysis of mitosis revealed a significant increase in the number of abnormal and 
multipolar figures in HTC/C3 cells while only slight alterations were found in SW1736 and no 
alterations were found in TPC1 (Fig 10A). 
Fig 10. Mitosis morphology. Cells were exposed to SP600125 or DMSO for 96h and then cells stained with 
Phospho Histone H3 (Red), DAPI (Blue) and tubulin (Green). All images were acquired with 60x immersion 
objective with ulterior 2.5 zoom.
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These mitotic abnormalities are the possible cause of the nuclear alterations previously described 
as multipolar mitosis are known to generate poliploid cells with giant lobated nuclei or to 
generate micronuclei as result of unbalanced chromosome segregation.
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5 EFFECTS ON MICROTUBULES
5.1 SP600125 INDUCES MICROTUBULES ALTERATIONS
Although very interesting, p21 involvement was only partially responsible of  SP600125 effects 
and other mechanisms are required. As long as one of the main actor in mitosis progression is the 
mitotic spindle, requiring intact microtubules dynamics and p53 mutations are known to confer 
high susceptibility to microtubule poisons, further experiments were performed in this direction. 
First of all it was investigated if SP600125 was able to induce alterations in tubulin 
polymerization.
Fig 11. Effects on microtubules. Cells were incubated with SP600125 10μM for the indicated period of time and a 
tubulin fractioning assay was performed. A: representative images of tubulin polymerization and acetylation 
variations; B: variations in tubulin polymeric and monomeric fractions inrealtion to total tubulinamount; C: 
variations in different tubulin fractions acetylation. 
A tubulin fractionation assay was performed and results analyzed by western blotting; it can be 
noticed that SP600125 induced a significant increase in the fraction of polimerized tubulin 
compared to the monomer form in cell lines with p53 impairment, with higher effects after 72h 
(Fig 11B). Moreover in p53 mutated cells this alteration was accompanied by a strong increment 
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in the acetylation of the polymer form, a marker of microtubule stability (Fig 11C).
Fig 12. Effects on acetylated tubulin morphology. Cells were incubated for 96h with DMSO or SP600125 for the 
indicated concentrations and then immunofluorescence performed. SP10 SP600125 10μM, SP20 SP600125 20μM.
Furthermore confocal microscopy analysis of tubulin acetylation showed not only a general 
increase but a complete upheaval of  microtubule architecture in HTC/C3 cells: while in 
untreated cells it was clearly recognizable the typical polarization of acetylated fibers emerging 
from the MTOC, in treated cells they appeared thicker, widespread through the cytosol without 
an organizing center and completely unrelated to the nucleus; only slight effects could be noticed 
in p53 null SW1736 cells while no effects were detected on wild-type TPC1 (Fig 12).
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6 EFFECTS ON CELL MOTILITY
6.1 SP600125 AFFECTS CELL MIGRATION
As long as intact microtubular dynamic is required for cell migration, a wound healing assay was 
performed to highlight if this skill was compromised. As it can be seen 16h post wound TPC1 
completely recovered while in HTC/C3 no progression was detected, demostrating a severe 
impairment of cell mobility; SW1736 showed an intermediated phenotype (Fig 13).
Fig 13. Effects on cell motility. Cells were incubated for 72h with DMSO or SP600125 at the indicated 
concentrations, scraped with a p200 tip and images acquired at 0 and 16h. A: representative images acquired at 0h 
(To) and 16h (CTRL, SP10 and SP20); B quantitative analysis of wound repair.  SP10 SP600125 10μM, SP20 
SP600125 20μM.
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6.2 SP600125 CAUSES ALTERATION IN PROTEINS INVOLVED IN CELL MIGRATION
To further characterize the effects of SP600125, different proteins were analyzed  in HTC/C3 
cells using Human Phospho-Kinase Antibody Array by R&D System.
The results showed that there were different levels of involvement in SP600125 action. 
First of all three different group could be noticed: the first one (Fig 14A) included proteins 
undergoing only slight variations, the second one (Fig 14B) included proteins with mean increase 
after SP600125 exposure and the third one (Fig 14C) included proteins with more than a two-
fold increase after SP600125 exposure. Of noticeable interest, the proteins detected in the third 
group are, from the lower to the highest one, FAK, GSK3β, STAT5b, Lck, Fgr, and β-catenin; all 
of them are involved in cellular adhesion and migration.
Fig 14. Plotting of SP600125/CTRL phosphorilation ratio. Cells were incubated with 10μM SP600125 or DMSO 
for 60h and then the assay was performed. A, B, C represents different subgroups corresponding to different fold 
changes in kinases phosphorylation; most interesting proteins are reported above each group.
Being  β-catenin the most affected, further experiments were performed.
Morphological analysis of migrating HTC/C3 cells demonstrated striking β-catenin localization 
differences following SP600125 treatment. In control cells β-catenin staining clearly marked the 
leading edge of migrating cells highlighting typical structures such as lamellipodia and filopodia 
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while in treated cells not only β-catenin was missing from cell front but instead it strongly 
stained intercellular junctions, indicating absence of single cell migration and permanence of 
adhesion (Fig 15). 
Fig 15.  β-catenin localization in migrating cells. Cells were exposed to SP600125 or DMSO for 72h,  scraped 
with a p200 tip and after 16h stained with WGA and then immunofluorescence was performed. Images show 
different cellular morphology at the wound edge, with 4x magnification in the lower raw.
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6.3 SP600125 AFFECTS HDACs ACTIVITY
HDAC6 is an histone deacetylase responsible of the regulation of tubulin acetylation and b-
catenin degradation; for this reason its activity was investigated to elucidate wether this enzyme 
was involved in SP600125 mechanism of action. Unluckily there was no availability of direct 
assays for HDAC6 activity in cellular extracts. Therefore a general HDACs activity assay was 
performed on concentrated cytoplasmic extracts, as HDAC6 and HDAC10 accounts for the 
major part of cytoplasmic HDACs activity. 
Fig 16. Effects on cytoplasmatic HDACs activity. Cells were incubated for 72h with DMSO, SP600125 10μM or 
TSA 5μM and a colorimetric assay was performed on cytoplasmic extracts.  SP10 SP600125 10μM, TSA5 
Trichostatin A 5μM. 
The results showed that after SP600125 exposure there was a significant decrease in HDACs 
activity in HTC/C3 cells and, with lower intensity, in SW1736. Only a slight decrease was 
detected in TPC1 cells (Fig 16). All the cells promptly responded to exposure to Trichostatin A, a 
well known HDACs inhibitor.
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SP500125 is a multi-kinase inhibitor that has recently been shown to be a promising, selective 
anticancer drug [57, 204-205]. In the last five years it has been proved able to induce 
endoreduplication and subsequent polyploidization in treated cells but there are contrasting 
results about its intracellular actions and there is no certainty on the specific mechanism of 
action. Depending on cell type, concentration and time of incubation opposite results have been 
obtained [52, 56, 206-208].  
Most of the studies postulated that SP600125 effects are a direct results of JNKs inhibition, 
anyway no specific connection was ascertained [52, 205-206]. Besides the effects on JNKs, the 
only known direct interaction that has been charachterized is with MPS1, a fundamental protein 
in mitotic spindle assembly checkpoint [55]; anyway even in this case there are contrasting 
results as SP600125 has been proved to have no effects on MPS1 in immortalized human BJ-Tert 
fibroblasts [54].
In 2012, in a small molecule screening, SP600125 resulted the more effective in inhibiting p53 
deficient cancer cells growth [57]; even in this case there are previously contrasting results 
showing no differences between p53 wild type and null cells [207, 209-210]. On this subject it 
has to be highlighted that all studies were conducted comparing the same cell line in different 
conditions, by silencing wt p53 or by transfecting it into null cells thus creating artificial 
imbalances in cell growth.
With this premises the aim of the current study was to characterize SP600125 mechanism of 
action. For this purpose six thyroid cancer derived cell lines with different p53 status were used. 
Of noticeable interest for the first time SP600125 effects were investigated on three different p53 
status spontaneously occourred, revealing new and promising effects like the ability to partially 
restore p53 function. In addition SP600125 action was investigated with a wider perspective 
revealing at the same time the less known effects on microtubule and cell migration as well as 
the interconnections between these pathways.
First of all, we analyzed the effects on p53 protein. The results demonstrated  that SP600125 is 
able to induce p53 nuclear translocation and subsequent phosphorylation at serine 15 in p53 
mutated cells (Fig 2,4); no previous data exist about this modification while there is consensus 
about the lack of action on p53 transcriptional activity in p53 wt cells [207, 210]. Moreover this 
p53 phosphorylation is at least partially responsible of p21 induction (Fig 5). The effects of 
SP600125 on p21 levels have been well described, anyway there are discordant hypothesis about 
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the underlying mechanism depending on cell type and treatment concentration [208, 210]. The 
group of Moon recently proposed that high doses of SP600125 are able to induce p21 through 
Akt and ERKs; in this work the two pathways were partially responsible of p21 alterations and 
no intermediate effector between SP600125 and Akt or ERK was found [52]. Being SP600125 a 
multi-kinase inhibitor it can be hypothesized a simultaneous action on different pathways 
resulting in p21 induction.
As no alterations of p53 phosphorylation were previously reported, different assumptions can be 
made to explain this effect. 
The first hypothesis involve a direct interaction between SP600125 and p53. An increasing 
amount of small molecules that are able to restore transcriptional activity of mutated p53 has 
been described, including PRIMA-1, MIRA-1, NSC319726, WR1065 [211-214]. Treatment with 
these compounds often result in p53 phosphorylation at serine 15 and p21 induction, a similar 
effect to SP600125 one [212, 215]. It must be remembered that cancer cells harbouring p53 
mutations usually have oncogenic lesions or damage signals capable of potently activating p53 
and thus its restoration causes much more dramatic effects than simple p53 activation in normal 
wt cells; this fact can explain why of the three p53 status examined, mutated cells resulted the 
most affected by SP600125 treatment [216-218]. Moreover cell lines used in the current study 
harbour different p53 mutations that affect the β-sandwich structure of the protein and  β-
sandwich mutants are the most promising target for rescue by small compounds, as stabilizing 
the affected protein in the wt conformation is often sufficient to restore its activity [219-221].
The second hypothesis involves microtubule alterations as a possible cause of p53 activation. Up 
to date there are no significant studies on SP600125 effect on microtubules with the exception of 
a study reporting that high doses (200μM) of SP600125 are able to induce spontaneous tubulin 
polymerization in an in vitro assay [208].  Accordingly to these results, our study shown an 
increase of microtubule stability starting after 24h of incubation while most dramatic changes are 
detected after 72-96h (Fig 11, 12). In accordance with this data coimmunoprecipitation assay 
shown that p53-tubulin binding reach a peak between 24 and 48 hours of incubation (Fig 3), 
exactly when microtubule dynamics are already affected but tubulin still maintain the nuclear-
periphery polarization. In literature there is abundant evidence that alterations of microtubules 
dynamics lead to p53 pathway activation but various mechanism have been postulated. The 
historical theory is that alterations of microtubule dynamics brings to aberration in spindle pole 
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formation and in chromosome disjunction, with consequent formation of poliploid cells and 
micronuclei, both of them being able of activate p53 [87, 222-224]. This process anyway is not 
able to explain the activation of mutated p53 and should be considered not as the principal cause 
but as the final effect of SP600125 induced alterations, as p53 inactivation is known to confer 
hypersensibility to microtubule interacting drugs. Recent studies suggest that suppression of 
microtubule dynamics in interphase cells leads to a more stable tubulin network, allowing 
efficient molecular transport and thus enhancing p53 nuclear translocation [225-226]. It was also 
demonstrated that microtubule alterations and DNA damage induce p53 phosphorylation at 
different residues, being serine 15 and threonine 18 the most frequent in the first case and serine 
20 and serine 46 in the second one [226-228]. 
The third hypothesis involves the previous ones as well as cell migration: it has been 
demonstrated that alterations of microtubule dynamics in interphase cells induces an increase in 
number and size of focal adhesions; this process is accompanied by activation of FAK and 
MAPKs that in the end trigger p53 activation [229-231]. In this case we have to remember that 
SP600125 inhibited cell motility through the involvement of microtubule, β-catenin, GSK3 and 
FAK pathways (Fig 13,14,15) and that previous activation of ERK pathways was hypothesized 
as SP600125 mechanism of action on p53 [52]. 
Given the importance of SP600125 effects 
on microtubules and cell adhesion we will 
proceed to examine these results in detail. 
The results shown that SP600125 is able 
to alter microtubule dynamics as shown 
by increase in acetylation levels and 
changes in morphology. In treated cells 
there was first an increase in the intensity 
of acetylated tubulin signal and after 48h a 
complete subversion of microtubule 
architecture (Fig 11,12). As it can be seen 
from the scheme microtubule are usually 
directed from a perinuclear MTOC 
constituted by centrioles toward the cell 
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Schematic rapresentation of microtubule alterations in 
control (up) and treated (down) cells. Microtubules are 
represented in green, nuclei in blue.
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periphery while in treated cell they appear to be widespread through the cytoplasm without any 
apparent polarization. Moreover treated cells microtubules have the typical features of 
microtubule bundles, structures formed by more microtubule packed together by specific 
proteins like CLASP and cis1p [232-233]. The formation of disorganized bundles is a well 
known effect of microtubule stabilizing agents like taxanes and epothilones and depends upon 
direct drug-tubulin interactions [234-237].
Although microtubule alterations are considered indipendent from p53 or at least acting 
upstream, the dramatic morphological changes in tubulin architecture were found only in the p53 
mutated cell lines, with very slight effect on the p53 null one; this is probably due to p53 
reactivation that seems to play a fundamental role in SP600125 actions on microtubule.
Even if it is not possible to determine which one of these two events trigger the other one and 
abundant contrasting literature exist on this point, it is a fact that both of them equally contribute 
in generating abnormal mitosis and subsequent cell death by mitotic catastrophe (Fig 9, 10). On 
one side p21 induction has been demonstrated responsible of SP600125 induced 
endoreduplication [56, 208, 210] creating polyploid cells, on the other side microtubule 
dynamics alterations, together with the already described MPS1 inhibition, are responsible of 
chromosomal segregation alterations, multipolar mitosis formation and impaired cytodieresis 
[54, 166, 223]. Following microtubule poison treatments most of cells undergo one or two round 
of abortive mitosis, become unable to progress further and finally die. The polyploid ones that 
manage to survive have been reported to became prematurely senescent [238-240].
In agreement with what has been reported, after incubation with SP600125 the characteristic 
morphology of senescent cells could be detected: cells appear flattened, bigger, with increased 
amount of vacuoles and more disomogeneous 
cytoplasmic content; nuclei were giant, 
polylobated or multiple and micronuclei, 
cytoplasmic budding of chromatin fragments, 
increased nucleoli size and number, chromatin 
alterations with presence of disomogenities and 
heterochromatin condensation foci were 
detected (Fig 6, 7). 
If we analyze all the effect described in a time 
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Schematic rapresentation of major SP600125 induced 
alterations in p53 mutated cells through time (hours).
DISCUSSION
dependent manner is clearly visible that when p53, p21 and tubulin acetylation levels increase 
there is a sudden decrease in cell proliferation; moreover mitosis and morphology alterations 
appear with a slight delay, being a consequence of the other variations.
Anyway is still impossible to detect a possible link between p53 and tubulin alterations.
Apart of all these result a complete new effect of SP600125 have been demonstrated that is 
inhibition of cell migration by microtubule, β-catenin and HDAC6 modulation.  
First of all inhibition of microtubule dynamics is known to affect cell migration as different 
microtubule poisons abrogate cell motility when used at low non-cytotoxic concentrations [241-
243]. Various mechanisms have been proposed, including the impairment of the MTOC 
reorientation toward the leading edge, the inhibition of Rho GTPases and effectors by altering 
microtubule polymerization-depolymerization cycle, the inhibition of intracellular protein and 
vescicles trafficking and consequent lamellipodia formation, the alteration of microtubule 
integrin clustering together with HSP90 degradation [244-247].
Of all this alterations, results shown that in SP600125 affected cells there is a total absence of 
MTOC organization and a significant alteration of late endosomes/lysosomes morphology and 
localization (Fig 8). Consequent morphologycal analysis of wound edge cells revealed that, 
while control cells migrate toward the free space with the classical morphology, treated cells 
extend stuctures similar to lamellipodia 
toward the wound but remain stuck to 
each other (Fig 15). The inability of 
detaching from other cells is confirmed 
by the intense β-catenin staining at 
intracellular adherens junctions. 
Moreover a protein phosphorylation 
array analysis revealed the involvement 
of different kinases that are fundamental 
in cell adhesion and migration like FAK, 
GSK3, Lck and to a lesser extent Src, 
Fyn And Yes (Fig 14).
Very interestingly both tubulin and  β-catenin are regulated through acetylation levels by 
HDAC6 and the activity of this enzyme appears to be reduced in a way that is direct proportional 
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Schematic rapesentation of control (left) ant treated (right) cells 
at the end of a wound. Arrow indicates migration direction, 
green represents β-catenin, red cell membrane and adhesions, 
blue nuclei.
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to cell proliferation inhibition. 
On the relation between HDAC6 activity and p53 reciprocal influence there is plenty of literature 
but contrasting hypotesis are reported. Of given importance HDACs inhibitor are a new 
promising anticancer drugs that are currently undergoing many clinical trials and one of them is 
already approved for T-cell lymphoma [248-249]. Indeed recent studies provided evidence that 
HDAC6 inhibitor act preferentially on p53 mutated cell lines because they are able to destabilize 
the mutated protein by alteration of its interaction with HSP90 and, at the same time, they are 
able to stabilize wt p53 through increased acetylation [250]. Effects on HDACs provide another 
interesting interconnection between p53, microtubule and  β-catenin alterations that can be found 
in SP600125 affected cells.
Moreover a direct action of SP600125 in HDAC6 and migration regulation can be hypothesized. 
In a wide range kinase inhibitor specificity screening study, SP600125 was identified as being 
able to inhibit ROCK2 activity [48]. This kinase is involved in regulation of RhoA as well as 
actin and intermediate filaments dynamics and recent studies unveiled a specific pathway linking 
it to microtubule and  β-catenin [157, 251]. ROCK2 is able to phosphorylate TPPP1 inducing its 
detachment from HDAC6; free cytoplasmic HDAC6 is fully functional and acts on microtubules 
and  β-catenin. In our working hypothesis SP600125 inhibits ROCK kinase activity thus 
preventing TPPP1 release of HDAC6 and explaining why a decrease in the deacetylase activity 
was detected without any changes in total protein amount. Inhibition of HDAC6 causes 
subsequent hyperacetylation of tubulin, leading to alterations in microtubule dynamics, and of  β-
catenin, leading to ubiquitination sites masking and preventing its proteasomal degradation; 
moreover β-catenin acetylation inhibits its cleavage locking it to cell membrane and inhibiting its 
nuclear translocation thus inhibiting another proliferation pathway often hyperactivated in 
human cancers [251-252].
In conclusion the current study confirmed previously reported data about SP600125 induction of 
endoreduplication and unveiled completely new features that can be explained by its multikinase 
inhibition activity. First of all SP600125 action is directed preferentially against p53 mutated cell 
lines without any relevant effect on p53 wild type cells; as second thing it seems able to restore 
p53 activity in mutated cell lines; third it affects HDAC6 activity providing new powerful 
anticancer effects: it alters microtubule dynamics and  β-catenin localization thus impairing cell 
migration.
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From these results SP600125 is proved to be active both on cell replication and cell diffusion, 
owing the potential to be a promising therapy for p53 mutated cancers as limitating drug for cells 
growth and metastases spreading.
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Schematic representation of different pathways involved in SP600125 action. Previous studies demonstrated 
the effects on MPS1, ERK and p21 inducing endoreduplication while the current study demonstrated 
involvement of p53 and MSK1/2 phosphoylation, HDAC inhibition, microtubule and  β-catenin involvement 
in mitosis progression, senescence induction and motility inhibition. Continuous lines represent 
demonstrated interactions while interrupted lines represent hypotesized ones.
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